Sirius XM has quietly become one of the most hated stocks on the market.

Over the past two years, SIRI collapsed from nearly $60 to just above $20. Subscriber growth flatlined. The media dismissed it as “radio in decline.” And most investors walked away without looking back.

But someone else walked in.

Berkshire Hathaway now owns more than 35% of the company.
They just added another 2.3 million shares this spring — a $54 million bet that the market is wrong.

The setup is classic Buffett:

1. A misunderstood business

2. Generating real cash

3. Returning it to shareholders

4. Trading at a deep discount

Today, SIRI trades at just 6–8× forward earnings and 7× free cash flow.
It’s buying back shares. It’s paying a 4.6% dividend. And it’s still embedded in 67% of new cars sold in America.

This is not a growth stock, but it is a cash cow — mispriced by a market that stopped caring.

Valuation and Cash Flow

SiriusXM isn’t trying to be the next Spotify or Netflix.
It doesn’t need to be.

The bull case starts — and mostly ends — with the numbers.

At ~$20/share, SiriusXM trades around 6–8× forward EPS and roughly 7× 2025 free cash flow.
That’s on $1.15 billion in expected FCF this year, rising from $1.0 billion in 2024. By 2027, they’re aiming for $1.5 billion.

This isn’t speculative. The cash is real. It’s recurring. And it’s being returned.

Buybacks: Over the past decade, Sirius has repurchased nearly half its float.
The current $1.17 billion authorization remains active.
Dividends: A $0.27 quarterly payout yields ~4.6% — well above the 10-year Treasury. The payout ratio? Below 40%.

Most media companies are burning cash. Sirius is printing it.

“Free cash flow conversion is expected to reach 44% of EBITDA in 2025.”
That’s margin expansion in a flat-revenue business.

It may not grow fast. But at these multiples, it doesn’t need to grow at all.

Stabilizing Subs: In-Car Is Sticky

This is where the bears get it wrong.

Yes, subscriber numbers have declined.
But under the surface, the trend is improving — and the in-car business is holding strong.

In Q1 2025:

• Net self-pay subscriber losses were 303k, a 16% improvement YoY

• Churn dropped to 1.6%, even after price increases

• Most attrition came from one-time factors: click-to-cancel rules, trial timing, and plan hikes

In other words: the customer base isn’t crumbling. It’s adjusting.

And SiriusXM is adjusting too — by doubling down on the car.

90% of its subscribers use SiriusXM in-car.
That’s where the product is sticky.

Recent moves:

• 360L platform now live in Tesla and Rivian, expanding reach in EVs

• Streaming access for 2M+ Teslas

• Revamped used-car trial program to target secondary buyers

Meanwhile, new modular pricing is opening the funnel:

• $9.99/month “music-only” in-car tier (launched Q1)

• Ad-supported tier coming later this year, designed for price-sensitive users

This isn’t about expanding the TAM — it’s about defending ARPU and keeping churn low.

And the early results say: it’s working.

Cost Discipline and Capital Allocation

When revenue growth is scarce, discipline becomes the edge. SiriusXM knows it.

Over the last two years, they’ve cut $350 million in costs. Now they’re targeting another $200 million in savings by year-end 2025 — trimming low-ROI marketing, cutting non-core bets, and consolidating tech platforms.

This isn’t lip service. The margin impact is real.

Despite flat revenues, adjusted EBITDA is expected to hit ~$2.6B in 2025, only slightly below 2024 levels — because cost cuts are doing the heavy lifting.

Capital allocation remains tight:

• $700M in debt is being paid down this year, dropping net leverage to ~3.6× EBITDA

• Buybacks continue, with over $1.1B still authorized

• The dividend is safe, fully covered by cash flow

Management isn’t chasing growth.
They’re optimizing a cash machine.

In a market obsessed with top-line stories, SiriusXM is quietly compounding on the bottom line. I like growth just as much as anyone, but these deep value plays have worked well for me over the years.

The Catalysts Wall Street Is Missing

SiriusXM isn’t priced like a company with upside.

But there are several levers in motion — and the market has largely stopped paying attention.

First, the long-awaited ad-supported tier is scheduled to launch in the second half of 2025. This opens the door to a large cohort of listeners who’ve historically balked at price — younger users, casual users, and those who already pay for other streaming services. It won’t move the revenue line overnight. But it could begin to reverse the narrative that SiriusXM is priced out of the mainstream.

Second, the Howard Stern contract is up for renegotiation. Stern accounts for a significant portion of paid listening hours, and his renewal (or replacement) will have real implications for retention and content spend. A favorable outcome here — even just stability — would reassure a market that still sees legacy content deals as ticking liabilities.

Then there’s the EV pipeline. Tesla and Rivian integrations are already live, and SiriusXM has been quietly expanding its OEM relationships. The company’s 360L platform makes in-car streaming seamless, even for electric vehicles that don’t include traditional satellite receivers. As EV penetration grows, so does Sirius’s footprint — especially through used-car resales, where SiriusXM continues to embed trial offers.

And finally, the short interest is worth noting. Roughly 10% of the float is sold short — one of the highest levels in a decade. That doesn’t guarantee anything. But it does mean that any positive surprise — a good quarter, a content deal, signs of subscriber stabilization — could force some fast reassessments.

In sum: SiriusXM isn’t dependent on a single breakthrough. But it has a half-dozen quiet catalysts that could stabilize the core business or nudge sentiment in the right direction.

Mispriced, Misunderstood, But Not Missing

This isn’t a high-growth media stock.
It’s a high-margin utility for commuters — and it’s trading like a melting ice cube.

That mismatch is the opportunity.

SiriusXM isn’t trying to reinvent itself. It’s returning capital, cutting costs, defending its in-car stronghold, and adapting its pricing to meet the moment. It doesn’t need subscriber growth to justify the current price — it just needs stability.

At ~7× free cash flow, with a 4.6% dividend and meaningful buybacks, the stock doesn’t need a hero narrative. It just needs to keep doing what it’s doing.

Berkshire’s stake — now over 35% — suggests that’s exactly the bet being made:
No reinvention. No moonshot. Just steady cash flow, patiently compounding, while the market looks the other way. As usual, I’m trading this by selling puts and using the premium to buy the underlying.

SiriusXM isn’t for everyone.
But for value-focused investors, the signal is a lot stronger than the noise.

Short-term interest sounds great — until Argentina and the U.S. both want a bite.

That’s my situation. Two tax systems. No tax treaty. And no clean way to hold cash without watching the yield get carved up before I ever spend it. Treasury bills? Taxed as ordinary income. Money markets? Same story. I could earn 5% on paper and walk away with 2% in practice — if I was lucky.

So I started digging.

I wasn’t looking for a trade. I was looking for a tool — something that could hold capital safely, keep it liquid, and stop bleeding return to annual taxes. Something that worked with an options-heavy strategy. Something built for taxable accounts. Something efficient.

I found BOXX.

This isn’t a traditional ETF. It doesn’t hold bonds. It doesn’t pay dividends. It doesn’t even look like it’s doing much. But under the hood, it’s running a strategy that mimics T-bill returns using options — and converts what would normally be taxed as interest into long-term capital gains.

It’s not magic. It’s structure.

And for investors who care about taxes — or who, like me, have no choice but to care — it’s a rare kind of breakthrough: a cash substitute that doesn’t punish you for waiting.

What follows is how it works, why it matters, and where it fits in a strategy like ours.

Why BOXX Matters in My Situation

I live in the uncomfortable overlap of two tax systems.

As a U.S. citizen, the IRS wants its cut. Every year. On every dollar. No matter where I live. And as a tax resident of Argentina — a country that treats even modest interest income like it's windfall profit — I get taxed again. No treaty. No credits. Just two governments, one pile of savings, and no clean escape hatch.

So when short-term rates surged in 2023 and 2024, most investors got excited. Suddenly cash was yielding 5%. High-yield savings accounts were back. Treasury bills finally paid more than lint. But for me, every basis point of interest was a liability. That 5%? Closer to 2.5% after Argentina took a slice. Lower still after U.S. taxes kicked in. The “risk-free” rate wasn’t risk-free at all — it came with guaranteed erosion.

Naturally, I started looking for a workaround.

And here’s what clicked: BOXX.

BOXX isn’t trying to pay you interest. It’s trying to look like interest, while not being taxed like interest. That distinction, subtle for most, changes everything for people like me. Because capital gains — even short-term ones — don’t trigger Argentine ordinary income tax rates. And in the U.S., BOXX’s structure means I can eventually claim long-term capital gain treatment — often at half the rate I’d otherwise pay on interest.

That makes it one of the only places I can park dollars without getting penalized twice.

There’s no form I have to file. No workaround to explain. Just an ETF that tracks Treasury returns — but via options trades — and keeps its yield hidden inside the share price. From the outside, it looks like a slightly sleepy fund with no dividends. From the inside, it’s quietly building return — and deferring tax — in exactly the way I need.

It’s not a loophole. It’s not aggressive. It’s just... efficient.

And for once, I get to be on the right side of that.

What BOXX Actually Does

BOXX isn’t a bond fund. It doesn’t hold cash. And it doesn’t pay interest.

Instead, it does something a little weirder — and a lot smarter.

BOXX makes money by lending cash into the options market through a structure called a box spread. If you’re already familiar, great. If not, don’t worry — you don’t need to master the mechanics. Here’s the simple version:

Imagine you could give someone $950 today and get exactly $1,000 back one year from now — guaranteed, no matter what the market does. That’s the entire premise of a box spread. It’s a synthetic loan. The $50 difference is your “interest.” Except it’s not taxed as interest. It’s the byproduct of a perfectly hedged options position.

And BOXX runs these trades over and over — not yearly, but every 1–3 months — using deep liquid S&P 500 index options. It’s not betting on direction. It’s not taking market risk. It’s just using the options market as a place to park cash with a defined payoff at expiration.

Importantly, BOXX does all this inside an ETF shell. So as a shareholder, you never see the trades. You don’t have to manage anything. You’re just holding a share of a fund that gradually increases in value, mimicking the return of short-term Treasuries — without ever touching a bond.

That’s the magic.

There are no monthly interest payments. No dividend declarations. No statements saying “you earned X in income.” Instead, your account value simply ticks up. The growth is real — but it’s invisible to the taxman until you sell.

And because the trades themselves are in index options (which qualify under Section 1256), the IRS treats the gains as 60% long-term and 40% short-term, no matter how short the actual holding period inside the fund. So BOXX wraps two tax advantages into one structure:

1. No taxable events while you hold.

2. Favorable tax treatment when you eventually sell.

For someone used to dodging landmines with every dividend, it feels bizarrely peaceful.

The Tax Alchemy — Why It Works (for Now)

Let’s start with the obvious: most cash yields are taxed poorly. Treasury bills? Taxed as ordinary income. Money market funds? Ordinary income. High-yield savings? Same story. If you’re in the top U.S. bracket, you’re losing up to 37% of that yield before it even hits your account.

That’s already bad.

Now layer in a second tax system — one that also treats interest as regular income — and you start to see my problem. Every dollar of yield gets chewed up twice. The nominal return looks great. The after-tax return barely beats a mattress.

BOXX changes all that.

Instead of paying out interest, BOXX retains all returns inside the fund. The underlying options trades settle as gains, not income. So from a tax perspective, nothing happens until you sell your shares. And when you do — as long as you’ve held for over a year — the growth is taxed as long-term capital gains, maxing out at 20% federally.

But the real kicker? The deferral.

You’re not paying 20% every year. You’re paying it once — when you exit. That means your return compounds untouched. You’re earning a “pre-tax” yield on your post-tax dollars, year after year, with no leakage. That alone is a form of alpha.

Let’s make it concrete:

• If you hold SGOV or a money market at 5%, and pay 37% tax, your take-home is 3.15%.

• If you hold BOXX and earn 5% taxed at 20% (eventually), your take-home is 4%.

• Add in tax deferral, and the effective rate jumps to something like 4.07%–4.15%, depending on how long you hold.

That spread — almost a full percentage point — is enormous in cash terms. Especially when it applies to hundreds of thousands in reserve capital. Or, in my case, to capital that would otherwise get taxed twice.

But there’s a catch: you have to hold.

If you sell BOXX after 3 or 6 months, the gains are taxed at short-term rates. You still get deferral, but you lose the lower tax bracket. So the whole trick here depends on discipline. Park your funds. Leave them alone for a year. Then reap the rewards.

And that’s what makes BOXX so clever. It doesn’t try to trick the tax code. It just rearranges the pieces — converting taxed-every-year income into taxed-once gains. And because it’s wrapped in an ETF structure, it avoids the usual wash sale rules, dividend timing issues, and annual paperwork.

For high earners, the math is compelling.

For dual-taxed investors like me, it’s almost too good to be true.

(Which is why, in the next section, we’ll talk about whether it stays true.)

Institutional Leverage for Retail Use

If you’ve ever tried to build a box spread at a retail broker, you know the real risk isn’t the trade — it’s the platform.

The structure itself is straightforward. You want to lock in a risk-free return by buying one vertical and selling another — a synthetic loan. But most retail platforms won’t let you do that in a single trade. They don’t offer a “box spread” ticket. So you have to leg in.

And that’s where the risk creeps in.

You enter the first vertical. Then you go to build the second. Market moves. Liquidity thins. Or the quotes just don’t match up. Now you’re exposed — briefly, but materially — to directional risk you didn’t sign up for.

And even if the trade goes through, margin treatment is often a disaster unless you have portfolio margin — and most don’t. Let’s be honest: the last thing your broker wants is for you to borrow money via box spreads — and avoid their juicy 13% margin interest.

That’s how they make their money. BOXX… short-circuits that.

Because BOXX isn’t borrowing. It’s lending. At scale. Through institutional pipes. Fully collateralized and cleared via the OCC. No legging in. No mismatched quotes. No margin red flags. Just a wrapped, managed fund that does the hard part for you.

For a tiny fee — 0.19% — you get execution, scale, tax handling, and broker anonymity.

BOXX gives you the same payoff as a broker box spread, but without the platform gymnastics.

Performance vs. the Alternatives

Here’s the thing: if BOXX only matched T-bill returns, that would be enough.

Because you’re not buying BOXX for higher gross yield. You’re buying it for the after-tax outcome — the net result, not the headline number. But even if we ignore taxes for a second, the truth is: BOXX actually holds its own.

In 2023, BOXX returned +5.04%. That’s nearly identical to SGOV’s +5.12% and slightly above BIL’s +4.94%. These are rounding-error differences — the kind you can chalk up to fee drift or small timing mismatches. More importantly, BOXX achieved that without taking meaningful extra risk.

The volatility? Tiny. The drawdowns? Almost nonexistent.

Over the past year, BOXX’s standard deviation hovered around 0.09%, while SGOV’s was about 0.05%. The difference is microscopic — especially when we’re talking about an ETF that holds no bonds, takes no market exposure, and is built entirely on options. BOXX’s NAV just… ticks upward. Slowly. Predictably. Like a cash alternative should.

And here’s where things get interesting: BOXX doesn’t pay out dividends. It doesn’t send you a monthly interest payment. The return is retained in the share price. That’s not a bug — that’s the point. It defers taxation. It avoids triggering events. It lets the compounding do the work inside the wrapper.

So yes, if you’re someone who needs monthly income, BOXX might look quiet or even underwhelming. There’s no dopamine drip. But if you care about keeping what you earn — especially in a taxable account — BOXX has delivered exactly what it’s supposed to.

It tracks. It compounds. It doesn’t create problems come April.

The tradeoff is this: you give up a little transparency and immediacy (no cash flow), in exchange for better tax treatment, more control, and a cleaner balance sheet. Instead of a dozen interest line items, you get one capital gain when you exit — on your terms, at your timing, ideally after 12 months.

Which brings us back to the core idea: BOXX isn’t about squeezing an extra basis point. It’s about avoiding leakage. And when you compare its execution to traditional T-bill ETFs or money markets, the evidence is clear:

You get the same ride. But you keep more of it.

The Risks Nobody Should Ignore

Let’s not kid ourselves. BOXX is clever — maybe a little too clever.

And that’s the risk.

Not volatility. Not liquidity. Not even the counterparty structure. The real threat is that one morning, the IRS wakes up, looks at this fund, and says: “Wait, you’re telling me this thing is effectively paying interest… but taxing it like a capital gain?”

Because yeah — that’s exactly what it’s doing. Legally. Transparently. But arguably pushing right up against the line.

BOXX works today because it wraps box spreads inside an ETF structure. The spreads themselves settle as gains (not income) under Section 1256. And the ETF avoids taxable distributions through in-kind redemptions. It’s a perfectly legal structure — for now.

But tax law isn’t static. And the IRS doesn’t love when everyday investors start using tricks that used to be reserved for hedge funds.

A former Treasury official called BOXX “a tax gimmick in a box.” That’s not the kind of quote you want to see. And there’s precedent for rule changes. Congress has already closed other loopholes involving derivatives, structured notes, and mutual fund timing schemes. They don’t always act fast — but when they do, they rarely act gently.

If the IRS or Congress decides BOXX is too aggressive, a few things could happen:

• They could reclassify its gains as ordinary income, retroactively or prospectively.

• They could strip Section 1256 treatment from box spreads held in ETFs.

• They could require funds that behave like fixed-income to distribute income annually.

Any of those would kill the edge. The ETF might still function. It might even still return 5%. But the whole point — deferring tax and converting interest into long-term gains — would vanish overnight.

Would they act retroactively? Probably not. But we don’t know. And that uncertainty — that policy risk — is the single biggest reason not to go all-in.

Because you’re not just betting on box spreads working. You’re betting on the tax code staying still. You need to determine if that is an acceptable risk for your scenario.

Now, let’s be clear: I’m not saying BOXX is a house of cards. It’s well-designed. Fully collateralized. Cleared through the OCC. There’s no leverage. No hidden derivatives. Just a smart structure that uses the rules as written.

But the more popular it gets — and with $6+ billion under management, it’s already on radar — the more likely someone starts asking uncomfortable questions. So I hold BOXX. But I also know there is a possibility that it could get nerfed. Because in the end, this isn’t about credit risk or market risk. It’s about political risk.

Where This Fits in My Strategy

In my Collateral Compounding strategy, idle cash is dead weight.

I’m constantly deploying buying power: selling puts, rolling exits, layering into positions. Every dollar that isn't working drags down the overall return. But being 100% allocated is a mistake too. Because when the market offers you gift, you need the ability to act.

That's why real liquidity matters.

Cash is the reload button. It lets you press advantage. It keeps you from becoming a forced seller. And it gives you control over timing — especially when markets don’t.

BOXX is my solution for that in-between zone. It gives me three things I care deeply about:

• 1. A place to park excess funds
  Capital that isn’t allocated right now but might be tomorrow needs a home that earns something — without creating tax friction. BOXX earns T-bill-like yields while deferring taxes, which keeps return compounding until we actually need it.

• 2. After-tax efficiency
  Most short-term cash parking solutions leak value to taxes. BOXX doesn’t. It turns “waiting” into “quiet compounding” — and keeps more of the gain in our pocket when we finally realize it.

• 3. Firepower on standby
  Whether it’s covering a rare assignment, doubling into a high-conviction name, or posting collateral for new trades, BOXX lets us stay liquid without sacrificing yield. It’s a sleeping asset that wakes up instantly when we need it.

And maybe there’s a little poetic justice here.

As options sellers, we’ve built our strategy on collecting premium. BOXX does the opposite — it lends liquidity back to the options market through synthetic interest. It’s a round-trip that feels oddly fair.

We take from the options market when it’s paying us. And now, when we’re not deploying, we lend to it. On terms we like.

Who BOXX Is For — And Who It Isn’t

BOXX isn’t for everyone. But for the right kind of investor, it might be the best cash tool available.

If you’re holding short-term reserves in a taxable account, BOXX gives you a rare edge: T-bill-like yield, deferred taxation, and the potential to convert that yield into long-term capital gains. It’s quiet. It’s passive. And it avoids the annual haircut that most cash alternatives take for granted.

But the benefit only matters if you’re actually paying tax.

So let’s be honest about who this isn’t for:

• If you hold cash in an IRA or 401(k): Skip it. You’re already tax-deferred. BOXX just adds complexity and fees for no advantage.

• If your income puts you in the 0%, 10%, or 12% bracket: You’re not paying much (if anything) on interest anyway. The whole “conversion” benefit becomes moot.

• If you need access in under a year: BOXX works best when held for 12+ months. Sell early and you lose the long-term gain treatment — which is the main point.

But if you’re in a high tax bracket — or if you, like me, get taxed twice because of where you live — BOXX isn’t just a nice idea. It’s a real solution.

And if you’re a non-U.S. investor who is investing in U.S. markets? It’s a gift. The U.S. doesn’t tax capital gains for foreign investors. So by using BOXX, you can now earn short-term U.S. interest — synthetically — with zero U.S. tax liability. That’s not a loophole. That’s just how the rules work. And it’s hard to beat.

So no, BOXX won’t replace your core equity exposure. And it’s not meant to juice returns through some wild options strategy.

It’s a tool. A place to park dollars safely — and keep more of what they earn.

For the right investor, that’s more than enough.

In every one of those cycles, long-term Treasuries bottomed before the Fed started slashing rates. Yields peaked, growth slowed, and investors who waited for the official pivot missed the early move.

If history holds, this is when you start accumulating — not after the rate cuts, not after the recession headlines, but now.

Three years ago, I said plainly: bonds were a bad bet. Prices were near all-time highs, yields were scraping zero, and the math just didn’t work. That call aged well. Long bonds were one of the worst-performing assets of the last cycle.

But the cycle is turning. Inflation has cooled. The Fed is on pause. Growth is rolling over. And for the first time in years, long-term Treasuries aren’t priced for disaster. They’re priced for doubt — which is exactly when they get interesting.

This isn’t about yield. It’s about macro conditions. And those conditions are beginning to look like every other moment when duration outperformed.

I Called the Top, Here’s Why That Matters

In late 2020, with yields scraping the bottom of a 40-year decline, I wrote something blunt to friends and family:

“Bonds will never again be as expensive as they are today.”

That wasn’t hyperbole. That was math.

After decades of disinflation and falling rates, the 10-year Treasury yield had collapsed to just 0.5% during the depths of COVID panic. Investors were still piling into long-duration funds because that’s what had worked — but the logic had broken. The engine of bond returns had always been falling yields. And yields, quite literally, couldn’t fall much further.

The consequence was baked in. Every incremental rise in rates would crush the value of long-term bonds. And that’s exactly what happened.

Over the next three years, those funds got obliterated. A 1% rise in rates meant a 15–20% drawdown. A 2–3% move — which we got — halved some retirement portfolios built on the old 60/40 gospel. It wasn’t a black swan. It was gravity.

So why revisit bonds now?

Because the inverse is also true.

If the top in Treasuries came when rates couldn’t go lower — then the bottom starts forming when they’ve already risen too far, too fast, and the conditions that drove the selloff begin to reverse.

That’s where we are now.

And it’s why we’re finally willing to accumulate.

What’s Changed Since Then

Three years ago, the risks were one-sided: inflation rising, rates near zero, and the Fed hopelessly behind the curve.

Today, that’s flipped.

Inflation is no longer the fire it was in 2022. It’s now a fading threat. Headline CPI is sitting at 2.4% — almost back to target. Core inflation is still above that, but it’s stable. And most importantly, the underlying forces that drove inflation higher — wage spikes, goods shortages, energy shocks — are unwinding.

The Fed knows it. After hiking aggressively through 2022 and 2023, it paused in early 2025. At the June meeting, Powell made the pivot clear: they’re in “wait-and-see” mode, not in a rush to keep tightening.

Even quantitative tightening — the quiet shrinkage of the Fed’s balance sheet — has been dialed back. Treasury roll-offs were reduced from $25 billion a month to just $5 billion, a move that effectively eases pressure on long-term rates.

Markets are already looking ahead. Futures are pricing in at least two cuts before the end of the year. That doesn’t mean cuts are guaranteed. But it does mean the expectation is shifting — and that’s often all it takes for bond prices to start moving.

Because the turn doesn’t wait for the Fed.

It begins when inflation cools, the Fed pauses, and the market smells the pivot.

We’re there.

Signs of a Slowing Economy

If the inflation backdrop makes long bonds interesting again, the growth outlook may be what makes them compelling.

Start with the leading indicators. The Conference Board’s index has now declined for six straight months — a streak that historically signals recession risk. It fell –0.1% in May after a –1.4% drop in April, pushing the six-month average deep into negative territory.

Beneath that headline are familiar cracks: factory orders weakening, jobless claims rising, new housing permits down. The only recent bright spot was a short-lived stock market rebound, and even that was driven by a tariff rollback, not underlying strength.

The labor market — still officially “healthy” — is softening too. Unemployment is hovering in the mid-4% range. Job growth has cooled. And the number of people collecting benefits is climbing.

Consumer confidence? Falling. Business sentiment? Weak. The manufacturing PMI has slipped below 50 — signaling contraction — and factories are shedding workers.

This doesn’t guarantee a recession. But it does mean the economy is losing steam.

And when growth fades, investors don’t reach for risk.

They reach for duration.

The Yield Curve Is Steepening — That’s Your Cue

For nearly two years, the yield curve has been deeply inverted. Short-term Treasuries yielded more than long ones — a classic warning sign that markets expect trouble ahead.

Now, that’s starting to change.

As of mid-2025, the curve has begun to dis-invert. The spread between the 2-year and 10-year Treasury, which was as wide as –70 basis points, has narrowed to around –15 to –20. It’s still inverted — but the trend has turned. And that turn matters.

Because the last phase of every inversion cycle is steepening.

Not because long yields spike — but because short yields fall faster.

That’s exactly what happens when markets expect Fed cuts. And it’s historically been a green light for long-duration bonds. Before the 2001, 2008, and 2020 recessions, the same pattern unfolded: the curve steepened before the Fed slashed rates, and long bonds rallied hard as front-end yields dropped.

This is the endgame of an inversion — and it’s a powerful setup.

A steepening curve tells you the market thinks monetary easing is coming.

And if that’s true, long Treasuries are exactly where you want to be.

The Auction That Spooked Everyone and What Happened Next

The May 21 auction of 20-year bonds wasn’t great. Bid-to-cover came in weak, demand looked shaky, and yields jumped above 5%. It was the kind of result that gets framed as a warning: too much debt, not enough buyers, the market blinking.

For a few days, that narrative stuck. Yields ticked higher. Commentators resurfaced the usual questions — about foreign demand, fiscal sustainability, the appetite for duration.

Then the next auction came. And the one after that.

On June 11, the Treasury sold $39 billion in 10-year notes. It cleared easily — in fact, the yield came in below where traders expected. That’s a strong bid. The very next day, a 30-year auction followed. Again: solid demand. Not blockbuster, but firm enough that yields dropped by five basis points in the aftermath. If there was real panic in the system, that’s not what it looks like.

What we’re seeing instead is digestion — not rejection. The market absorbed the May wobble, recalibrated expectations, and stepped back in. Yields on the long end have since drifted lower. And that’s telling.

Because if the bond market were truly breaking, auctions would be getting worse. Instead, they’re stabilizing. That’s not noise. That’s support.

You don’t need foreign buyers to carry the whole market. You just need confidence that someone — pension fund, insurance desk, U.S. household — is willing to lock in 4.8% for the next three decades. And right now, they are.

The May scare didn’t derail the turn in Treasuries. It clarified it.

The Playbook Hasn’t Changed, Just the Setup

Every easing cycle looks a little different. But the bond market’s reaction to those cycles? That’s been remarkably consistent.

When the Fed stops hiking and the economy starts to stall, long-term Treasuries usually move first — and fast.

In 2008, the 10-year yield dropped from nearly 4.7% to 2.5%. In 2019, when the Fed cut mid-cycle, it fell from 3.2% to 1.5%. In early 2020, during COVID’s initial shock, it dropped under 0.5%. And in each case, long bonds rallied sharply — not after the Fed moved, but as the market began to price it in.

That’s what makes the current setup so familiar. The Fed is holding, not hiking. Inflation is back near target. Leading indicators are flashing slowdown. And the curve has already started to steepen. All of this is how those past rallies began.

You don’t need to predict the exact bottom in yields. You just need to recognize the pattern — and position before the herd catches on. Here’s how I’m doing it.

Long bonds aren’t a trade on current policy. They’re a bet on where policy has to go if growth slows and inflation stays contained. That’s the bet we’re starting to make.

This Isn’t a Call on Rates — It’s a Shift in Regime

I’m not forecasting the next CPI print or guessing whether Powell cuts in September. That’s noise. What matters is that the direction of pressure has changed.

Inflation is no longer accelerating. Growth is no longer resilient. And the Fed is no longer hiking. That’s a different world than the one that punished bondholders over the past three years.

You don’t need to love long bonds to see their place in this environment. You just need to accept that the risk is no longer all one-sided. Yields are elevated. Duration is hated. And the setup — economically, cyclically, historically — looks familiar.

That doesn’t mean we go all in. But it does mean we stop sitting it out. We called the top when it mattered. Now we’re starting to lean the other way.

Here’s the full setup:

Entry

Sold SIRI Aug 15 2025 $22 Put (51 DTE)
SIRI250815P00022000

Opened:        June 25, 2025
Entry Price:   $1.15
Exit Target:   $0.15 (To Close)

Underlying:    $22.48
Buffer:        2.13%
Breakeven:     $20.85

Max Risk:      $2,200.00
Return:        4.55%
Prob. of Win:  ~59%

Profit Target: $100.00

Trade Thesis

I just opened a new position in SiriusXM — selling the Aug 15 $22 put for $1.15 with 51 days to expiration. It’s not a flashy trade, but that’s the point. At just under 2% out of the money, this put lets us quietly collect $100 of premium while anchoring our basis below $21 on a name that’s trading at ~7× forward earnings and still returning nearly $700 million to shareholders this year.

This is a classic collateral compounding setup. We’re not betting on a turnaround. We’re collecting income while the case builds underneath. Subscriber churn has started to stabilize. EV integration is picking up speed (Tesla and Rivian both support SiriusXM streaming now). And the company is finally showing discipline on costs — targeting $200 million in additional savings this year, on top of the $350 million already achieved.

Most importantly, this is still a cash flow machine. Free cash flow is expected to hit $1.15 billion in 2025, with a dividend yield pushing 4.6% — all while they actively buy back shares and pay down debt. If the $22 level holds, we keep the full premium. If not, we’re happy to own the stock below breakeven and start building a long-term position. Either way, the math works in our favor.

The delta on this put is 0.41 — so the odds are a coin flip in theory. But if subscriber trends continue improving and new pricing tiers bring in fresh demand (the ad-supported tier launches later this year), we like our chances. We’re not trying to time a bottom. We’re just building our exposure one layer at a time — and this is where we start.

Status: Open

14 gigawatts of interest.
A reactor that doesn’t need refueling for a decade.
A $3 billion market cap.

That’s the setup. It’s not a moonshot. It’s a bet on electricity demand, execution, and the fact that the U.S. military just picked this company to power a strategic Arctic base.

We’re not betting the farm.
But we are building a position.

This is our first entry into Oklo — a small nuclear company with a big plan: reinvent fission for the 21st century. If they pull it off, they’ll have a head start on one of the most durable problems in modern infrastructure: how to deliver clean, reliable, 24/7 power anywhere it’s needed.

What follows is a breakdown of the tech, the thesis, the risks, and how we’re trading it. Because whether you believe in nuclear or not, power demand is rising — and someone has to supply it.

What Oklo Actually Does

Oklo isn’t trying to rebuild the past. It’s trying to rethink how nuclear works from the ground up — with a compact, self-regulating fission reactor that doesn’t need water, pumps, or even daily supervision.

The company’s flagship design, the Aurora, is a fast-neutron fission reactor. It uses HALEU (high-assay, low-enriched uranium) fuel and circulates heat through liquid metal (sodium), not pressurized water. That choice matters. Unlike the large, complex light-water reactors that make up most of the world’s nuclear fleet, Oklo’s design doesn’t require massive steam turbines, external cooling towers, or human operators on constant watch. It’s small enough to fit on a few acres — and stable enough to run for a decade without refueling public_substack_style.

Each Aurora unit is designed to generate up to 75 megawatts of electricity — or 125 megawatts of thermal energy — with over 90% uptime. And it’s not just the fuel cycle that’s long-lived. The Aurora’s core is built to be sealed and buried, with natural convection and heat pipe-based cooling systems that require no external power to function. It can sit quietly in a remote location, deliver 24/7 baseload power, and shut itself down if something goes wrong — all without operator intervention.

Instead of selling reactors, Oklo plans to build, own, and operate its fleet — selling electricity to customers under long-term contracts. This matters for investors. It turns the company into a future nuclear utility, with recurring revenue tied to 20–30 year power purchase agreements. Not a one-time vendor.

In other words, Oklo isn’t a reactor company. It’s a power company — built on nuclear fission that looks nothing like what came before.

Why It’s Different from the Reactors You’ve Heard Of

When most people hear “nuclear,” they think of disasters. Chernobyl. Three Mile Island. Fukushima. Giant containment domes, spinning turbines, emergency core cooling systems — and human error waiting to happen.

Oklo’s Aurora reactor isn’t just a different model. It’s a fundamentally different design — with physics, fuel, and control systems that make those old risks structurally impossible.

Start with the core. Traditional reactors use water to both cool the fuel and slow down neutrons — which means they run at high pressure, with complex systems of valves and pumps. When one of those fails, or when operators make the wrong call (as they did at Three Mile Island), the system can spiral out of control in minutes.

Aurora doesn’t use water. Its fuel is cooled by liquid metal, and the reactor operates at atmospheric pressure, not hundreds of pounds per square inch. There are no high-pressure steam loops, no massive turbine buildings, and no cooling towers. Just a sealed, passively cooled unit — buried underground — with inherent negative reactivity feedback. If temperatures rise, the reaction slows. If they fall, it picks back up. No operator needs to touch a thing.

Chernobyl failed in part because of a positive void coefficient — a fancy way of saying the reactor got more reactive when things got hot. Aurora is the opposite. Its feedback loops are self-correcting — more like a thermostat than a chain reaction gone rogue.

It’s also small by design. Traditional reactors produce 1,000+ megawatts and require vast infrastructure. Aurora’s 75 MWe footprint is modular and distributed. That’s not just safer — it’s more flexible. Power can be placed closer to where it’s used: data centers, industrial sites, military bases. And each reactor can run for 10 years or more without refueling, which means no complex logistics, no routine shut-downs, and fewer opportunities for anything to go wrong.

There are no analogues in the traditional fleet. This isn’t a scaled-down Three Mile Island. It’s a fundamentally new system — one that removes the most dangerous parts of nuclear before they ever appear.

The Bull Case for OKLO

The bull case isn’t built on vibes. It’s built on numbers — and the numbers are impressive.

Oklo’s disclosed pipeline has grown from under 1 GW in mid-2023 to over 14.1 gigawatts today. That’s a 2,000% increase in just one year . For context, the entire nuclear generating capacity of the United States is about 95 GW. Oklo’s pipeline — if fully realized — would be the equivalent of adding 15% more nuclear capacity to the U.S. grid, using reactors that fit in a parking lot.

Much of this interest is already taking shape as commercial intent. In 2024, Oklo signed a 20-year master agreement with Switch, a data center operator with some of the most demanding uptime and power quality requirements in the industry. That deal alone accounts for 12 GW — nearly 85% of the pipeline. While it's non-binding at this stage, it's a clear signal: customers want Aurora deployed at scale .

And it’s not just Switch. Oklo has also signed:

• A 50 MW deal with Diamondback Energy to power oilfield operations,

• A 100 MW agreement with Wyoming Hyperscale, and

• Letters of intent with Equinix, another major data center provider.

Meanwhile, the Department of Defense awarded Oklo a 30-year contract to deploy a microreactor at Eielson Air Force Base in Alaska. The project is expected to be operational by the early 2030s — and if successful, it opens the door to additional government sites, especially in remote or vulnerable areas .

That’s demand. Now here’s the capacity plan.

Oklo’s first commercial deployment is scheduled for 2027–2028, with plans to scale rapidly thereafter. Their internal projections (from investor materials and public filings) suggest a ramp to several gigawatts in the first five years. If they manage even 25% of the 14.1 GW pipeline by 2032, that implies:

• ~3.5 GW deployed,

• At 90% capacity factor, that’s ~27.5 million megawatt-hours per year,

• At $90/MWh (a conservative PPA price for clean, reliable baseload), that’s $2.5 billion in annual revenue.

And that’s just the base energy sales.

Oklo is also developing fuel recycling capabilities, targeting a long-term reduction in fuel cost by as much as 80%. They recently acquired Atomic Alchemy, a radioisotope producer, for $25 million — giving them potential entry into the $55 billion global isotopes market .

All of this is happening with a market cap around $3–4 billion.

So the math looks something like this:

• ~$3B market cap today

• $2B+ in potential annual revenue within 5–7 years

• 14 GW pipeline

• Government and enterprise customers willing to sign 20–30 year deals

This isn’t a hype stock. It’s a pre-revenue utility with institutional backing and a regulatory tailwind at its back. And the upside, if execution lands, is many multiples from here.

Section 4: The Risks We're Not Ignoring

The upside here is real. But so are the risks. This isn’t a core position. Not yet. And if we’re being honest, there are a few ways this could go sideways.

The biggest one is regulatory. Oklo hasn’t submitted its final license application yet. Their first attempt, back in 2022, got rejected — not because the tech failed, but because the documentation was incomplete. That’s been addressed. But until the NRC signs off, none of this ships. The company says they’ll file by the end of 2025. That’s a hard milestone. If it slips, the entire deployment timeline could move with it.

Then there’s the fuel. Aurora runs on HALEU — a next-generation uranium fuel that’s in short supply. The U.S. is building domestic capacity, and Oklo is well-positioned to be early in line. But if HALEU isn’t available at scale by 2027, no one is flipping the switch.

Execution risk matters too. Oklo’s not just trying to build reactors. It’s trying to stand up an entire vertically integrated power business. That means manufacturing. Siting. Licensing. Financing. Operating. Doing that once is hard. Doing it fifty times in five years is even harder.

The good news? They have the cash to try. After their latest raise, Oklo is sitting on roughly $660 million in liquidity — enough to fund operations through at least 2028, even if revenue takes longer than expected. That’s a bigger cushion than most pre-revenue power startups ever see.

Still, it won’t be enough forever. If the company hits delays — or scales more slowly than planned — it will need to raise again. That’s not a knock, just reality. And in a market that punishes early-stage names on any slip, even a strong long-term story can see its stock cut in half on weak execution.

That’s why we’re treating this like what it is: a venture-stage power company, not a cash-flowing utility. We’re not swinging big out of the gate. We’re sizing for uncertainty — and scaling with proof and milestones.

How We’re Trading It

We’re not just researching Oklo. We’ve started building the position.

We’re tying our entry to something concrete: the company’s first military reactor contract. The Air Force intends to award Oklo a 30-year agreement to build and operate its Aurora reactor at Eielson Air Force Base in Alaska — a landmark deal that validates both the technology and the business model.

This is exactly the kind of milestone we wait for: institutional commitment, long-term cash flow visibility, and a federal partner that doesn’t move casually. It’s not revenue yet. But it’s real.

We’ll continue to build our exposure conservatively — using put premium to fund future entries, scaling as execution plays out. There’s no rush.

You can read the full trade breakdown here:

On June 24, I sold the TLT Aug 29 $85 put for $1.17. When TLT shows some strength I’ve been doing selective positions at this strike.

Here’s the full setup:

Entry

Sold TLT Aug 29 2025 $85 Put (66 DTE)
TLT250829P00085000

Opened:        June 24, 2025
Entry Price:   $1.17
Exit Target:   $0.17 (To Close)

Underlying:    $87.43
Buffer:        2.78%
Breakeven:     $83.83

Max Risk:      $8,500.00
Return:        1.18%
Prob. of Win:  ~69%

Profit Target: $100.00

Trade Thesis

I picked the $85 strike for a reason. It’s not just round — it’s real. That level has acted as strong support for TLT twice in the past year, once in October 2023 during peak-rate panic, and again this spring as yields retested their highs. Both times, buyers showed up. Both times, the downside stopped there. When you're selling puts, you want to plant your flag where others have already drawn a line — and $85 is that line.

At the time of trade, TLT was trading around $87.40. That gives us a cushion of about 2.8% — not massive, but meaningful in a low-volatility product like Treasuries. More importantly, we're not targeting a moonshot rebound. We're selling a put at a level we’d be willing to own long bonds, in a product that’s already been battered by two years of rate hikes. We’re collecting $117 in premium against $8,500 of notional exposure, aiming to close the position once we’ve captured $100 of that. That’s a 1.18% return over 66 days — with a probability of profit around 69%, based on delta.

Technically, the setup’s clean. TLT just bounced off that $85 zone again, and it's trying to reclaim short-term moving averages. RSI has turned up from oversold. Volume’s not screaming “breakout,” but it doesn’t need to. What we’re looking for is stability. If the Fed holds and the market stops pricing in another hike, long bonds don’t have to rip — they just need to stop falling.

That’s the real thesis here. You’re not making a leveraged bet on a dovish pivot. You’re getting paid to take risk at a level that’s already proven its merit — while the market wobbles in between policy regimes. If we’re wrong, we get assigned at a price we’re willing to own or roll. If we’re right, we book $100, add to our long-term TLT position, and move on.

Status: Open

On June 24, I sold the SLV Sep 19 $30 put for $0.51. I’ve been accumulating silver during 2025 as an inflation hedge. This is a conservative play to continue to build my position.

Here’s the full setup:

Entry

Sold SLV Sep 19 2025 $30 Put (87 DTE)
SLV250919P00030000

Opened:        June 24, 2025
Entry Price:   $0.51
Exit Target:   $0.01 (To Close)

Underlying:    $32.455
Buffer:        7.57%
Breakeven:     $29.49

Max Risk:      $3,000.00
Return:        1.67%
Prob. of Win:  ~78.52%

Profit Target: $50.00

Trade Thesis

The gold–silver ratio isn’t just elevated—it’s flashing opportunity. Historically, when the ratio pushes above 80, silver tends to mean-revert aggressively. Today, we’re hovering near 90. That’s despite silver’s recent rally and despite a surge in industrial demand. It’s a signal that silver hasn’t even caught up yet. Gold already made its move—hitting all-time highs this spring. Silver is still playing catch-up. But in this kind of macro environment, catch-up can turn into breakout fast.

Because the truth is, the Fed hasn’t solved inflation. Rates are high, yes. But so are deficits. So is housing. So are input costs in just about every industrial supply chain. Even with CPI cooling on the surface, stickier categories—services, rents, insurance—aren’t budging. And the longer the Fed keeps rates elevated without bringing inflation all the way down, the more they box themselves in. You don’t get to hold 5% policy with 6% borrowing needs forever. Eventually, something gives.

In that backdrop, hard assets become more than just inflation hedges—they become policy hedges. Gold has already priced that in. Silver hasn’t. And with industrial demand tightening the float and ETFs reloading positions, the supply side isn’t prepared for a wave of investment flows. If the Fed cuts, silver runs. If inflation sticks, silver runs. If both happen? That’s how you get to $40, $50, or higher.

So no, we’re not chasing the move. We’re positioning into it. Selling puts at $30 with the intent to own—because the setup favors silver, the macro regime favors silver, and the ratio is still doing most of the talking. It’s not about calling a top in gold. It’s about seeing that silver hasn’t started yet.

Status: Open

On June 24, I sold the OKLO Aug 15 $55 put for $6.75, banking on a high-probability setup sparked by the company’s most transformative announcement to date.

Here’s the full setup:

Entry

Sold OKLO Aug 15 2025 $55 Put (52 DTE)
OKLO250815P00055000

Opened:        June 24, 2025
Entry Price:   $6.75
Exit Target:   $1.75 (To Close)

Underlying:    $58.96
Buffer:        6.72%
Breakeven:     $48.25

Max Risk:      $5,500.00
Return:        9.09%
Prob. of Win:  ~70%

Profit Target: $500.00

Trade Thesis

Earlier this month, the Department of the Air Force issued a Notice of Intent to award Oklo a contract to design, build, own, and operate its Aurora microreactor at Eielson Air Force Base in Alaska. This is no pilot program. It marks the first-ever military deployment of a commercial advanced microreactor—a major leap forward for both the company and U.S. defense energy policy.

The reactor will provide electricity and heat to a strategic Arctic installation, supporting mission resilience in harsh environments. It will operate under a long-term power purchase agreement (PPA)—validating Oklo’s business model, not just its technology.

This aligns perfectly with a string of recent federal executive orders urging the rapid deployment of advanced nuclear systems on U.S. military bases. In short, Oklo is now the tip of the spear in making that vision real.

The implications are massive:

• Institutional validation from the U.S. military.

• A de-risked path toward future federal deployments.

• Proof-of-concept for commercial-scale PPAs in defense.

With the stock trading near $59, this $55 put sale gives us $6.75 of premium and a 6.72% downside buffer. The breakeven sits at $48.25, below any realistic retracement bar a market-wide collapse.

We’re targeting a $500 per contract profit by closing at $1.75 or lower—locking in a strong return while keeping risk defined and asymmetric.

This is a bet on progress—and the Pentagon just made Oklo’s future far more concrete.

Status: Open

You’ve got the portfolio. You’ve got the buying power. You’re ready to build long-term exposure without tying up cash.

But if you’re using Robinhood or SoFi — or any platform that caps you at basic options access — this strategy is dead on arrival.

Collateral Compounding works because it taps into margin capacity — not idle dollars. You’re not parking cash. You’re not borrowing funds. You’re simply using the value of the positions you already own to secure new ones.

That requires selling uncovered puts.

And most brokers won’t let you do that by default. Some won’t let you do it at all.

This post is about making sure you’re not stuck. We’ll walk through:

• Why uncovered puts are essential to the strategy

• Which brokers support them (and which don’t)

• What level of access you actually need

• How to get approved — and what to do if they say no

Because if your broker won’t let you use the margin you’ve earned — it might be time to find one that will.

Why This Strategy Requires Uncovered Puts

Most people think of puts as something you buy when you’re bearish — or something you sell when you’re sitting on a pile of idle cash. That second version — the cash-secured put — is what most brokers let you do. It’s simple. It’s safe. It’s easy to explain to compliance.

But it’s not what we’re doing here.

Collateral Compounding doesn’t use cash to secure puts. It uses Reg T margin. That means your broker needs to let you sell uncovered puts — positions backed not by idle dollars, but by the margin capacity already available from the stocks you own.

You’re not borrowing. You’re not paying interest. But you are pledging a portion of your portfolio as collateral — and that requires a higher level of options access.

Think of it this way:

• Cash-secured puts require you to set aside the full cost of the stock. Sell a put with a $50 strike, and your broker will want $5,000 in cash, locked up until expiration.

• Uncovered puts, by contrast, use Reg T margin. Your broker sets aside part of your account’s margin capacity — often 20–30% of the notional value — while your cash stays fully invested.

That distinction is what makes this strategy work. You’re putting unused buying power to work — not sidelining capital. But it only works if your broker allows uncovered puts under Reg T.

Why Not All Brokers Allow This

A lot of brokers love to advertise options access. But when it comes to actually selling puts the way this strategy requires — uncovered, margin-based, and cash-free — many of them quietly say no.

Some just don’t support it at all. Robinhood, SoFi — these platforms are built for beginners. They cap you at cash-secured trades. You can’t unlock Level 3 or Level 4 approval because those levels don’t exist. Even if your portfolio is ready, they’re not.

Others do support uncovered puts — but they make you jump through hoops to get access. You’ll need a margin account, a high enough account balance, and the right answers on your options application. (We’ll cover that next.)

That’s why choosing the right broker isn’t just a convenience issue — it’s a functional requirement.

We built a full comparison of major U.S. brokers — who allows uncovered puts, what level you need, and how much equity they require. You can view the full table here:

If your broker doesn’t make the cut, don’t waste time trying to bend the rules. Switch.

How to Get Approved

Even if your broker supports uncovered puts, they won’t just hand over access. You need to ask for it — and more importantly, you need to qualify.

The approval process usually happens through an online questionnaire. It’s designed to screen out anyone the broker thinks might misuse advanced options — which is reasonable. But it also means if you answer “safely,” you’ll get denied by default.

Here’s what they’re really looking for:

• A margin account (not a cash account)

• An investment objective of Speculation or Most Aggressive

• At least 2–3 years of experience with both stocks and options

• A stated tolerance for risk — even if your actual strategy is low-stress

In short: you need to signal that you know what you’re doing. That doesn’t mean exaggerating. But if you downplay your experience or risk tolerance, you’ll get placed in Level 1 or Level 2 — which only allows covered calls or cash-secured puts.

Level 3 or Level 4 is the target — depending on how your broker labels it. That’s what enables Reg T margin use for uncovered puts. And without that, you can’t run this strategy.

So take the application seriously. Answer like someone who’s managed their own money through a few market cycles — because if you’re here, you probably have.

What to Do If You’re Denied

Don’t panic. And definitely don’t give up.

Broker applications are conservative by design. They’d rather under-approve than overexpose. But that doesn’t mean their decision is final — and it doesn’t mean you have to accept it.

If you’re denied access to uncovered puts:

1. Call or message your broker. Ask them to review your application manually. Let them know you’re looking to use Reg T margin to run a structured put-selling strategy — not YOLO trades or deep leverage.

2. Clarify your intent. You’re not trying to speculate wildly. You’re managing risk carefully, using unencumbered buying power to build long-term equity exposure.

3. Remind them you’re the customer. If they won’t grant approval — even after review — let them know you’ll move your assets to a broker who will. (And mean it.)

You’re not asking for a favor. You’re asking for access to a well-understood strategy that’s already supported by most major platforms. You’ve done the work. You’ve met the thresholds. You’re qualified.

And if your broker doesn’t agree?

You know where to go.

The Bottom Line

Collateral Compounding only works if your broker lets it. This isn’t a theoretical barrier — it’s a real one. If you can’t sell uncovered puts using Reg T margin, you can’t run the strategy.

Some brokers make that easy. Others block it completely. And the rest bury it behind layers of forms, checkboxes, and assumptions about what kind of investor you are.

But here’s the thing: you’re the one in control.

If your current platform won’t grant access — push back. If they still won’t budge — move on. You don’t need to settle for a platform that keeps your capital boxed in.

The strategy is sound. The mechanics are clear. The approvals are within reach.

So get yourself set up right.

Your portfolio’s already working. Let it work a little harder.

That’s how far Target has fallen since its 2021 peak — a nearly 65% drawdown that looks, at a glance, like a broken business. But the stock chart doesn’t tell the full story. Because while the market kept selling, the business kept adapting:

1. It fixed its inventory problems.

2. It brought gross margin back to 28%.

3. It scaled digital sales to nearly 20% of total revenue.

4. And it transformed its nearly 2,000 stores into same-day fulfillment hubs — competing not just with Walmart, but Amazon.

This isn’t another department store getting e-commerce’d into irrelevance. Target made it through that war — and came out stronger. Yet the market still prices it like a dying mall anchor.

At today’s levels, you’re buying a $107 billion revenue business for 10.7x earnings — with a 4.5% dividend, $40 billion in owned real estate, and a margin recovery already in motion.

That’s not a speculative bet. It’s a valuation disconnect.

And for investors willing to be patient, that disconnect is the entire opportunity. Especially if you’re building exposure the way I am — using puts, not cash, and stacking ownership over time.

The Setup: Why Target Looks Broken (But Isn’t)

At first glance, the chart tells a simple story: Target peaked at $268.98 in November 2021. Today, it trades around $95 — a 65% drawdown that suggests something broke.

But the market’s narrative doesn’t match the company’s facts.

Yes, Target got hit in 2022. Inflation squeezed consumers, discretionary spending collapsed, and Target’s own inventory missteps forced heavy markdowns. Gross margins dropped to 23.6%, and the stock unraveled.

But since then? Margins have recovered. Inventory is clean. Store traffic is stabilizing. Digital sales are growing again. And operating cash flow last year more than doubled.

Meanwhile, Wall Street hasn’t noticed — or doesn’t care. Target now trades at just 10.7x trailing earnings, well below its 5-year average of 16–18x, and far cheaper than peers like Walmart (~23x) or Costco (~34x).

It’s not priced like a $100 billion revenue business. It’s priced like it’s in terminal decline.

And that’s the disconnect.

Because this isn’t Macy’s. It’s not Bed Bath & Beyond. Target didn’t get Amazon’d. It adapted. Its digital sales now account for nearly 20% of revenue. Nearly every online order gets fulfilled through its store network — lowering cost and boosting speed. Same-day fulfillment (Drive Up, Shipt) now powers more than a third of digital revenue. And its app sits in the pockets of 30 million Americans.

This isn’t a legacy retailer trying to play catch-up. It’s a modern, omnichannel operator that’s already done the work. The results just haven’t shown up in the stock yet.

The Core Business Still Works

This isn’t a company in secular decline. Over the last decade, Target has quietly grown revenue from $71 billion (2014) to $107 billion (2024) — a ~4% CAGR, despite macro headwinds and consumer volatility. Even with inflation-adjusted spending under pressure, the core engine is still running.

Same-store sales (comps) have been volatile, but the pattern isn’t collapse — it’s normalization. After pandemic-era comps surged +19% and +13% in 2020–2021, they fell -3.7% in 2023 as stimulus wore off and discretionary demand dried up. That’s not a broken business — that’s a reversion.

And while the headlines focused on shrinking foot traffic and markdowns, the mix quietly shifted in Target’s favor:

• Essentials and groceries now make up ~50% of total sales — a natural hedge during economic softness.

• Beauty and Food & Beverage comped positive in 2024, helping offset softness in home and electronics.

• Digital sales now account for nearly 20% of total revenue, up from just 5% a decade ago — a clear sign Target didn’t miss the e-commerce wave.

Importantly, margins are coming back.

After dipping to 23.6% gross margin in 2022, Target has recovered to 28.2% in the latest quarter — not far from its pre-pandemic average. Operating margins have also clawed back to 5.3%, and management is guiding for continued improvement in 2025.

That margin trajectory matters. At scale, even a 50–100 basis point improvement in operating margin adds billions in earnings power. If they reach a 6–7% range again — which they did as recently as 2021 — the earnings story flips quickly.

Add to that their ability to control costs — SG&A held flat in 2024 despite inflation — and you get a business that’s more efficient now than during the stimulus boom.

So no, this isn’t a growth rocket. But it’s a wide-moat operator, with a proven omnichannel platform, clean inventory, and a balanced category mix that can absorb consumer cyclicality.

In a world where most retailers are either dying, overstored, or overleveraged, Target stands out for what hasn’t changed — and what quietly has.

Real Assets, Real Value

Most investors see Target as a retailer. But on the balance sheet, it’s also something else: a quiet real estate empire.

Roughly 90% of Target’s stores are owned, not leased — a stark contrast to peers like Macy’s or department store chains that lease most of their footprint. Add in its distribution centers and owned land, and Target controls an estimated 254 million square feet of property.

That’s not just operational flexibility. It’s hard asset value.

Conservative estimates peg Target’s real estate portfolio around $40 billion, or about $60 per share. At today’s ~$95 stock price, that implies the market is only valuing the entire retail operating business at $35 per share.

Let that sink in: The brand, the stores, the digital infrastructure, the $100 billion in annual sales — all of it is being valued like a distressed department store with no future. Meanwhile, Target’s real estate sits there quietly as a built-in margin of safety.

But this isn’t just about what Target owns. It’s about what it generates.

• Operating cash flow: $8.6 billion in 2023

• Free cash flow after capex: $3.8 billion+

• Dividend payout ratio: ~49% of earnings — not stretched

• Dividend yield: ~4.5%, with a 52-year history of consecutive increases

• Net debt/EBITDA: ~1.5x, with an A credit rating

That means the dividend is sustainable, the debt is manageable, and the buyback authorization (currently $8.7B remaining) could easily resume once earnings stabilize.

It’s rare to find a retailer with this combination of cash generation, financial discipline, and unlevered real estate backing. Especially one that trades at just 7x EV/EBITDA, while Walmart trades at ~11x and Costco around ~18x.

The market sees earnings volatility. But the balance sheet says something else: this is a business with staying power — and asset support most retailers would kill for.

Valuation and Scenarios

Target’s current valuation looks like a market that’s priced in failure — or at least stagnation. But the underlying math tells a different story.

Right now, Target trades at:

• 10.7x trailing P/E (based on $8.86 EPS)

• ~11.9x forward P/E (using midpoint FY2025 guidance of ~$8 EPS)

• 7.0x EV/EBITDA

• ~0.53x EV/sales

• ~4.5% dividend yield, with a 49% payout ratio

Let’s translate that into scenarios.

Bear Case

Consumer spending remains weak, comps stay negative, and margins stall near 5%. EPS dips toward $7. The market assigns a depressed 13x P/E.

• Price Target: ~$90

• Downside: ~5%, mitigated by dividend yield

• Rationale: Prolonged inflationary pressure on essentials and continued discretionary softness

Bull Case

Discretionary demand rebounds, comps turn positive, and Target regains operating margin north of 6.5–7%. EPS hits $10+, and the multiple expands toward 16–17x.

• Price Target: $160–170

• Upside: ~65–80% from today’s price

• Rationale: Retail macro turns, inventory and shrink pressures ease, digital and store traffic both improve

Sum-of-the-Parts Reality Check

Even without a retail turnaround, the $40B+ real estate portfolio alone could justify $60/share in asset value. At $95/share, that implies you’re paying just $35 for the entire operating business — a business that’s still producing billions in cash flow and owns its store network.

In short, the downside is bounded by hard assets and cash flows. But the upside — if margins recover and the market rerates — could be 60–80% or more.

That’s exactly the kind of setup that Collateral Compounding is built for.

Why It Fits the Collateral Compounding Playbook

Let’s be honest: Target probably won’t rip tomorrow.

The main risk here isn’t that the business fails — it’s that the market keeps treating it like it already has. We might sit in a sideways range for months. Maybe quarters. This could be a drawn-out accumulation phase — the kind of grind where nothing happens until suddenly everything does.

But that’s exactly why it fits our strategy.

With Collateral Compounding, we’re not relying on price action to do the work. We’re not calling bottoms or waiting for a breakout. We’re getting paid to patiently build long-term exposure using margin capacity, not cash.

Target is the ideal candidate:

• It pays a 4.5% dividend, covered by strong cash flow.

• It trades cheap — meaning put premiums offer attractive yield relative to risk.

• Its downside is anchored by real estate and essential-goods revenue.

• And it’s backed by a brand, an omnichannel platform, and a management team that’s already fixed the biggest problems.

Every time we sell a put on Target, we’re taking the other side of that mispricing. We’re getting paid to accumulate equity in a high-quality business — at prices that reflect none of its long-term strengths.

And if it trades sideways for six months?

Great.

We’ll keep writing puts. We’ll reinvest the premium into stock. We’ll build a full position — slowly, deliberately — while others ignore it. Then when the rerating comes, it’s all upside.

This is what Collateral Compounding is made for: quiet accumulation in overlooked names, while the rest of the market waits for a headline. The disconnect is already here. Our job is to exploit it.

Mispricing Has a Clock. Not a Catalyst.

The market doesn’t need a press release to fix this.

Target doesn’t need a turnaround plan — it already had one. And it worked.

The reason the price hasn’t moved isn’t because the business is broken. It’s because most investors are still looking at the chart instead of the balance sheet. They’re trading headlines. We’re building positions.

This is what accumulation looks like: sideways price, slowly improving fundamentals, and a growing disconnect between what something is worth and what it costs. It’s uncomfortable. It’s quiet. And it’s usually when the best setups take shape.

That’s why we’re not in a hurry. We don’t need a short-term bounce. We just need time. And with the right structure — selling puts, reinvesting premium, compounding into a high-quality name while the market sleeps — we’re using that time to our advantage.

Eventually, value forces recognition. Until then, we’ll keep getting paid to wait.

On June 23, we opened a new position on Target (TGT) by selling the Aug 15, 2025 $90 put for $2.75.

That’s 53 days to expiration — plenty of time for this setup to play out.

Here’s the full setup:

Entry

Sold TGT Aug 15 2025 $90 Put (53 DTE)
TGT250815P00090000

Opened:        June 23, 2025
Entry Price:   $2.75
Exit Target:   $0.75 (To Close)

Underlying:    $96.01
Buffer:        6.26%
Breakeven:     $87.25

Max Risk:      $9,000.00
Return:        2.22%
Prob. of Win:  ~70%

Profit Target: $200.00

Why We Like It

TGT isn’t your typical retailer. It’s a survivor.

While others were gutted by Amazon or tripped over themselves online, Target adapted — and strengthened. Same-store sales have leveled off, but the business is leaner, margins have stabilized, and the balance sheet is solid. After collapsing from its $268 high in 2021 to under $100 today, the stock is now compressing — a setup that often precedes sustained accumulation.

We’re not chasing a rebound here. We’re positioning before it happens — selling puts to get paid while we wait and buying shares.

Status: Open

In just over a decade, Nubank (NU) went from a startup with a purple credit card to one of the largest digital banks on Earth — with 118 million customers, $3.2 billion in quarterly revenue, and net income of $557 million in a single quarter.

That kind of velocity doesn’t happen by accident. It happens when you combine a broken market with a better model — and move faster than anyone else.

Nubank didn’t invent digital banking. But it made it work at scale, in a region where most incumbents are still charging ATM fees and asking people come into branches and personally sign documents to open accounts. What started in Brazil is now unfolding across Mexico and Colombia, with the same signs of dominance: high engagement, low cost, and relentless product expansion.

And yet — despite the size, despite the profit — Nubank is still early. Only a fraction of its users treat it as their primary bank. Only a slice of Latin America has been converted. And only a small share of regional banking profits has shifted online. I live in Latin America. They are behind but will catch up eventually. And the digital players are going to win the market.

That’s the setup. The story isn’t about what Nubank has already done. It’s about how far it can still go — and whether the rest of the market has noticed. (Hint: It has not.)

The Setup: What Makes Nubank Different

In 2013, Nubank launched with a single product: a no-fee purple credit card for Brazilians fed up with paperwork, hidden fees, and branch lines. That one wedge — designed for a narrow slice of the market — cracked open the entire banking sector.

Today, it’s not a product. It’s a platform. Nubank serves 118.6 million customers across Brazil, Mexico, and Colombia, making it one of the largest digital financial institutions on Earth. It’s profitable, still growing >40% YoY, and has done it all without relying on traditional bank infrastructure.

But here’s the part that should make investors pay attention: despite that scale, Nubank is still early. It’s the primary bank for only ~30% of Brazilian adults, and it holds just ~3% of Latin America’s banking profits. Even in its home market — where it’s already the third-largest bank by customer count — the runway is massive.

The strategy is simple, but powerful:

• Win users with no-fee, digitally native financial products

• Use automation and mobile-first UX to keep costs low

• Layer in more services — loans, investing, crypto, insurance — and monetize through credit and engagement

• Replicate the model across other underbanked but smartphone-rich markets

That last part is key. Brazil was a test case. Mexico and Colombia are proving the strategy scales.

Nubank calls it the “infinite game.” But what they’ve actually built is a compounding engine — one where every new customer costs less to serve, every new product deepens engagement, and every year makes the platform more entrenched. Nubank is playing a different game than its peers.

Product Depth: The Platform Approach

Most neobanks build one or two features and try to scale them. Nubank is doing something else entirely.

They’re building a platform — not just to move money, but to manage every layer of your financial life. From simple savings to high-end travel perks, from budgeting tools to mobile service, the goal is clear: make Nubank the central hub for your wallet.

It started with a credit card. Then came NuConta, a free digital checking account with instant PIX transfers, debit functionality, and auto-yield “Caixinhas” savings buckets. From there, Nubank added personal loans, payroll loans, and working capital for small businesses — covering both consumer and SME credit.

That alone would make it a formidable challenger bank. But Nubank didn’t stop.

They acquired Easynvest to launch NuInvest, offering ETFs and self-directed brokerage access. They rolled out Nubank Cripto, enabling trading across 14 digital currencies — and are exploring tokenized government bonds. On the insurance side, they’ve launched fully digital offerings for life, auto, phone, and home — all priced for accessibility and structured with no hidden fees.

High-income customers haven’t been ignored either. Nubank’s Ultravioleta premium card comes with cashback, travel perks, and wealth management features. They’ve added multi-currency accounts via Wise, and even NuViagens, a travel-booking platform built into the app. Most of these products cross-sell into high-yield deposits like CDBs — which, in Brazil, come with deposit insurance — making them a safe haven for capital as well.

Then came the curveball: NuCel, Nubank’s own mobile phone service. It’s prepaid, contract-free, and deeply integrated — with rewards like extra data for savers. That’s not banking. That’s platform gravity.

In total, Nubank launched 45+ new products on their platform — ranging from “Turbo Caixinhas” (with 15% APY in Mexico) to digital coupons for visually impaired users. These aren’t random side bets. They’re hooks. Each new product keeps users on the platform longer, increases revenue per user, and strengthens Nubank’s hold on the daily habits of its customers.

This is what incumbents miss. They don’t just compete with one Nubank product. They compete with all of them — in one app, with one brand, at one-tenth the overhead.

The Monetization Engine

Nubank isn’t just growing fast. It’s monetizing at scale — with some of the strongest unit economics in global fintech. Let’s start with the headline number:

ARPAC (Average Revenue Per Active Customer) reached $11.20/month in Q1 2025, up 23% YoY on an FX-neutral basis.

That figure is impressive on its own — but what matters more is the direction and distribution underneath it.

ARPAC isn’t flat across cohorts. Mature users — those who’ve been with Nubank longer and adopted more products — are already generating ~$26/month, or $312/year. That’s higher than SoFi. These customers are increasingly sticky, use multiple services, and account for a growing share of revenue.

Even if Nubank stopped adding customers (not going to happen), the growth runway available to them just from upselling alone is enormous.

Engagement, CAC, and Cost-to-Serve

High revenue per user only works if you’re not spending too much to get — or keep — those users.

Nubank’s Customer Acquisition Cost (CAC) is low: $5–$7 per new user. For context, many U.S. fintechs pay upwards of $20–$40 via paid search and referral bonuses. Nubank benefits from virality, brand strength, and mobile-first onboarding — it’s become a default choice in Brazil, not a niche product.

That low CAC pairs with a high monthly active rate: 83%+ of users engage with the platform every month — that’s nearly 99M out of 118.6M customers. Most traditional banks would kill for anything close.

And then there’s the clincher: cost-to-serve.

Nubank spends just $0.70–$0.80 per active customer per month to operate the platform.

That covers everything: tech infrastructure, customer service, compliance, and backend operations. It’s a result of scale, automation, and the absence of physical branches. And it feeds directly into margins.

Profitability and Efficiency

Q1 2025 net income came in at $557 million, representing a net margin of 17% on $3.2B in revenue. That margin outpaces peers like SoFi, which posted $71M in net income on similar revenue (SoFi also uses accounting games to front-load their revenue) — and far exceeds cash-burning players like Dave, which lost money on just ~$100M in quarterly revenue.

Nubank’s efficiency ratio — the share of revenue consumed by operating costs — stands at ~25%. That means 75 cents of every dollar earned flows through as gross profit. Traditional banks often operate with efficiency ratios in the 60–70% range. Even the best-run retail banks rarely drop below 50%.

The difference is architectural. Nubank wasn’t retrofitted for digital. It was built for it.

What’s Behind the ARPAC Climb?

The company has multiple levers pushing monetization higher:

• Credit adoption: Interest income is rising as more customers take on personal loans, payroll loans, and grow card balances.

• Non-interest fees: Interchange, insurance premiums, crypto trading spreads, ATM fees, and NuViagens travel revenue all contribute to service income.

• Cross-sell: With 45+ products, the average Nubank customer now holds multiple accounts — deepening wallet share and raising revenue per user.

• Pricing discipline: With ROE exceeding 40% in 2024, Nubank isn’t chasing market share at all costs. It’s monetizing deliberately — and profitably.

And because they already run lean, every dollar of incremental ARPAC flows through at high margin. The platform scales without the overhead that drags on legacy players.

Takeaway

I live in South America. I am watching first hand as fintech players devour the traditional banks. Nubank, MercadoLibre, these are the companies that are going to control banking in Latin America 10 years from now. Nubank is executing. It's already profitable, already scaled, and already transforming how Latin America banks.

It’s built a platform where the unit economics compound: low acquisition costs, high engagement, multiple revenue streams, and a digital foundation that scales without friction. Add to that a massive underbanked population, rising product adoption, and the beginnings of geographic expansion — and you have a growth engine hiding inside a bank charter.

This isn’t SoFi trying to grind its way to profitability in a saturated U.S. market. It’s not Dave scraping interchange fees from gig workers. It’s a real bank — with real customers and real margins.

The risk is Latin America. The market will get upset every now and then when FX losses and political issues impact quarterly results. But I look past those things. I look at the growth story and the margins.

I'm doing weekly options trades on this name, selling puts when Nubank trades at the low end of its range and pouring the premium back into a long position. I'm building my $0 cost long position for as long as I can, each time the market offers me a nice entry.

That’s the trade. And if Nubank keeps executing, it won’t be a trade at all. It’ll be one of the defining growth stories in global fintech and a core part of my portfolio.

Most people hear margin and picture debt. They imagine interest charges, margin calls, and leverage gone wrong. They assume that using margin means borrowing — and borrowing means risk.

But Regulation T doesn’t work like a credit card.

If you’ve ever used a margin account to sell an uncovered put — especially as part of our Collateral Compounding strategy — you’ve probably noticed something odd:

• No money leaves your account

• No loan is issued

• And yet the trade goes through, and premium hits your balance immediately

What’s happening isn’t borrowing. It’s collateralization — and it’s governed by a rule most investors have never actually read: Reg T.

In this post, we’ll explain exactly how it works — where your buying power comes from, what your broker is doing behind the scenes, and why Reg T margin is the engine, not the enemy, behind this strategy.

By the end, you’ll know more about how your account works than 90% of investors.

What Is Reg T? (And Why It Matters Here)

Most investors never read the rules that govern their accounts. But every time you place a trade in a margin account, you're operating under Regulation T — a Federal Reserve rule that’s been in place since 1934. It was designed to limit excessive leverage during speculative bubbles. But in our case, it quietly powers everything we do.

So what is it?

At its core, Reg T sets the margin requirements for retail brokerage accounts in the United States. It tells your broker:

• How much you must deposit to buy stocks on margin (initial margin)

• How much you must maintain to keep those positions open (maintenance margin)

• And — crucially for us — how much collateral is required to sell options without cash backing them

In simple terms, Reg T governs how much of your existing portfolio can be used to support new positions.

Why It Exists

After the 1929 crash, regulators realized that investors were often trading with just 10% down — borrowing the other 90% to buy stocks. When prices fell, forced liquidations made everything worse. So in 1934, the Federal Reserve introduced Reg T to clamp down on that kind of leverage.

Today, Reg T limits you to 50% initial margin for most equity purchases. If you have a $100,000 portfolio, you can buy up to $200,000 worth of stock, assuming all securities are marginable. That’s 2:1 leverage — a far cry from the 10:1 practices of the 1920s.

But Collateral Compounding doesn’t use that buying power to load up on new shares. Instead, we use a small, controlled slice of it to sell puts — without posting a cash reserve.

How Reg T Applies to Our Strategy

When you sell a put in a margin account, you're not borrowing money. You're taking on an obligation — the potential to buy stock at the strike price. Reg T governs how much collateral must be set aside to support that obligation.

This collateral is not cash out of pocket. It's a slice of your portfolio’s existing value — a reserve your broker earmarks in case the trade goes against you. That’s what we mean when we say we’re using margin capacity: we’re tapping into a rule-based allowance based on the value of the stocks you already hold.

The exact requirement varies by broker and trade specifics — but the principle is consistent:

Under Reg T, you can write options without posting cash, as long as your portfolio can support the risk.

We’ll break down the specific math — with real trade examples — in a later section. For now, just know this:

Reg T isn’t a loophole. It’s the rule that makes Collateral Compounding possible.

Why We’re Not Borrowing

Think of your broker like a hotel. When you check in, they don’t charge your credit card for damages — but they do place a hold. That hold isn’t money spent. It’s just a safeguard. If everything goes smoothly, it’s released and the amount put on hold never hits your monthly statement.

Selling puts in a margin account works the same way. Your broker doesn’t hand you money or deduct from your balance. They simply set aside part of your portfolio’s margin capacity — just in case you get assigned.

But that’s not the whole story.

The Broker Isn’t Just Placing a Hold — They’re Checking Who’s Checking In

If you’re running a hotel and a quiet business traveler shows up, the hold might be small. But if a rock band walks in at midnight with three guitars and a fog machine, you’re going to be asking for a reserve for a lot more than the value of the minibar.

That’s how your broker thinks too.

• If you’re selling .30 delta puts on quality stocks, and only taking on assignment risk equal to 25% of your portfolio’s long value, the margin requirement — the “hold” — is modest.

• But if you’re selling at the money puts or calls, or putting on positions that could theoretically lose more than your entire portfolio is worth, the broker starts acting like a nervous hotel manager. The hold gets bigger. Fast.

Reg T gives brokers a framework for these decisions, and FINRA rules spell out the minimums. But the sizing is dynamic — based not just on the trade structure, but on how reckless you’re being.

That’s why Collateral Compounding stays well within the lines. We don’t max out. We don’t sell high-delta options. We don’t bet the house. We stay boring — by design.

The Key Distinction

We’re not borrowing. We’re not leveraging up.

We’re just securing smart obligations — modest, well-structured put positions — with excess margin capacity that’s already sitting in your account. No interest. No debt. No disruption to your core portfolio.

And if you run the strategy as designed — with defined sizing, low-delta entries, and clear exits — your broker barely blinks when you check in.

Where the Buying Power Comes From

If you own $100,000 worth of stocks in a margin account, you already have access to Reg T margin capacity — even if you’ve never used it before.

Under Regulation T, most marginable stocks can be purchased with 50% down. That means:

• Your $100,000 long portfolio supports up to $200,000 in total exposure

• You've already used $100,000 of that buying power to hold your existing positions

• That leaves you with $100,000 of unused margin capacity

This is the raw capacity your broker sees. But in our strategy, we don’t use all of it. Not even close.

Real Example: Selling a Put on NVDA

Let’s say NVDA is trading at $150, and you sell the $135 strike put, about two months out, with a .30 delta.

• You collect $4.30 per share, or $430 per contract

• You take on the obligation to potentially buy 100 shares at $135 — a total of $13,500 if assigned

That $13,500 is what we call your assignment budget. It’s the real-world risk — the cash you'd need if you were assigned the shares. And it's the number we use to size trades safely.

Reg T Margin Required for This Trade

Let’s see how much of your margin capacity this trade actually uses.

Using the Reg T formula for short puts:

Now let’s plug the numbers into our example and see how much margin is actually used for this trade:

Your broker sets aside $1,930 of your $100,000 margin capacity. That’s less than 2% of what’s available to you.

And notice the gap:

• You’ve taken on $13,500 of potential assignment risk

• But you’re only using $1,930 of margin capacity to support it

That’s the power of Reg T — and why our strategy works. Your margin account gives you far more capacity than you need, as long as you size trades thoughtfully and stay disciplined.

Assignment Budget vs. Margin Capacity

This distinction matters:

• Assignment budget: What the trade would cost if assigned — real money, real obligation

• Margin capacity: What your broker sets aside as collateral — not borrowed, just reserved

We cap your assignment budget at 25% of your portfolio when you’re starting out — that’s $25,000 on a $100,000 portfolio. And in practice, the actual margin requirement to support that entire $25K of potential risk might only be $3,000 to $5,000.

So while your broker sees room to let you swing a sledgehammer, we’re using that space to build with hand tools — carefully, selectively, and with a safety net under every trade.

Reg T vs. Portfolio Margin

If you’ve poked around your broker settings, you may have come across something called portfolio margin. It’s a more flexible margining system, typically available to accounts over $150,000 with higher risk tolerance and approval.

And yes — it can lower your margin requirements on certain trades.

But let’s be clear:

You do not need portfolio margin to run this strategy.

Reg T — the standard default for most brokerage accounts — gives you more than enough buying power. In fact, even under Reg T, you could sell puts representing up to 100% of your long portfolio value and still remain within the rules.

That’s the upper limit of what we’d ever recommend. In practice, we typically cap assignment risk at 25% for beginners and 50% once you’re ready — which means we’re using only a fraction of your margin capacity. So while portfolio margin might be helpful for some uses, it’s overkill here.

Reg T is simple, reliable, and entirely sufficient for compounding high-quality equity exposure using this strategy.

Margin Isn’t Our Enemy — It’s Our Engine

Most investors are taught to fear margin. And for good reason: used recklessly, it can blow up any portfolio, even one made up of quality stocks. But what we’re doing isn’t reckless. It’s structured, conservative, and designed to leave your core holdings untouched.

Reg T margin is what makes that possible.

It doesn’t lend us cash. It doesn’t charge us interest. It doesn’t interfere with what we already own. It simply recognizes that our existing portfolio has value — and lets us put that value to work.

That’s how we’re able to sell puts without spending cash and build new equity exposure — without ever pulling capital from what we already believe in.

You don’t need portfolio margin. You don’t need leverage. You don’t need complexity. All you need is a margin-enabled account, some unused buying power, and a plan for how to use it wisely.

Margin isn’t something to fear. It’s a tool — and in our strategy, it’s the engine that drives the whole system forward.

Used poorly, it can magnify mistakes. Used well, it quietly compounds your portfolio — one deliberate position at a time.

Here’s the full setup:

Entry

Sold NU Aug 1 2025 $11 Put (45 DTE)  
NU250801P00011000

Opened:        June 17, 2025
Entry Price:   $0.23
Exit Target:   $0.03 (To Close)

Underlying:    $12.10
Buffer:        9.09%
Breakeven:     $10.77

Max Risk:      $1,100.00
Return:        1.82%
Prob. of Win:  ~80%

Profit Target: $20.00

Thesis

NU has been bouncing in a tight range — and we’re using that to our advantage.

At around $12, the stock offers a clean setup to sell puts just under support. This week, we sold the 8/1 $11 put for $0.23. That’s a ~20 delta trade with nearly 10% downside cushion — and a high probability of success.

But this isn’t a short-term trade we plan to flip.

NU is a core position for us. And $11 is a price we’re happy to buy at. Selling puts here lets us build that position on our terms — with the added benefit of being paid while we wait.

If the stock holds above $11, we keep the premium and reset.

If it dips below, we take assignment and move to the next phase: covered calls.

What We Do With Assignment

We don’t roll these puts.

If we get assigned, we simply take the shares — and wait. NU’s trading range gives us flexibility. We’ll typically let it drift back toward $12, then start selling covered calls to generate more income. Or, if the stock looks particularly attractive, we may just hold the shares outright.

Either way, we’re fine owning NU. This strategy is about accumulating a core position at opportunistic levels — not avoiding ownership.

How It’s Managed

This is a true set-and-forget setup.

• No roll plan. If the stock breaks $11, we get shares — by design.

• Premium is realized at expiration if the stock stays above the strike.

• Covered calls come next — but only once the timing and price are right.

We’ll keep running this trade every few weeks as the opportunity presents itself. Same name. Same strike. Same playbook.

Over time, these small, repeatable moves build real ownership — without chasing, overpaying, or overreacting.

Status: Open

If you were watching Archer Aviation ($ACHR) last week, you saw a stock in free fall.

From $12.17 on June 11 to under $10 in just two days — a nearly 20% drop that erased recent gains. At first glance, it looked like something had gone wrong.

But that wasn’t the case. There was no earnings miss. No canceled contracts. No regulatory delays.

Instead, Archer raised $850 million in fresh capital — and the stock repriced accordingly. The selloff wasn’t panic. It was dilution math.

What’s been missed in all this: the company is actually stronger today than it was before the drop. It now has a $2 billion war chest, new global partnerships, and a tailwind from U.S. policy. One of the most important tech investors in the world just bought the dip.

If you’re a long-term investor, this wasn’t a warning sign. It was a buying opportunity disguised as volatility.

Before the Drop: A Surge of Optimism

The selloff didn’t come out of nowhere. In fact, just days before the dip, Archer was hitting new 52-week highs and gaining momentum.

Why? A few clear catalysts had lined up.

First, the White House issued an executive order supporting eVTOL integration — a formal move to accelerate air taxi adoption in the U.S. That’s not just symbolic. It signals that policymakers are ready to write clearer rules and potentially fund infrastructure. For Archer, it shortens the regulatory timeline and validates the entire business model.

Second, analysts took notice. On June 9, HC Wainwright raised their price target on ACHR from $12 to $18, citing the regulatory support and long-term runway. They weren’t alone — 7 out of 8 analysts covering the stock rated it a Buy by mid-June.

Investors responded. Archer’s CEO called the executive order a “seminal moment,” and the stock surged above $12 by June 11.

So when the drop came, it wasn’t because enthusiasm had faded. It was because the company raised money. And that’s where the story turns.

What Triggered the Drop

The sharp decline in Archer’s stock wasn’t random. It was a direct reaction to a capital raise — one that caught the market off guard, even if the rationale made long-term sense.

On June 12, just one day after closing at $11.73, Archer announced it would raise $850 million by selling 85 million new shares at $10 each. That’s about a 15% discount to the prior close.

This is where the reaction starts to make sense.

For existing shareholders, this wasn’t just a headline — it was dilution. When a company issues new shares, your ownership gets spread thinner. You still own the same number of shares, but they now represent a smaller piece of the pie. So the market did what it usually does in this scenario: it repriced the stock closer to the offering price.

By the next day, shares were trading around $10 — a textbook response to a discounted raise of this size. Volume spiked. Traders exited. The stock chart turned red. But nothing had changed in the business itself.

That’s the key point.

This wasn’t a funding crisis. Archer wasn’t scrambling for cash. In fact, the company already had over $600 million on hand. But aviation is capital-intensive, and management saw a window — both in terms of regulatory momentum and investor demand — to shore up the balance sheet ahead of major milestones.

There were other options. They could’ve raised debt. They could’ve done a convertible. They could’ve offered current shareholders the chance to participate. But they went with a straight equity raise, and they priced it attractively enough to bring in institutional buyers quickly.

In doing so, they made a deliberate trade: short-term pressure in exchange for long-term flexibility. And while the market dinged them for it, the fundamentals didn’t worsen. In fact, they arguably improved.

No revenue guidance was cut. No certifications delayed. No partnerships scrapped.

This wasn’t a company in trouble. It was a company preparing to scale.

What Changed (and What Didn’t)

Archer didn’t just sell shares — it added nearly a billion dollars to its war chest. That single move took the company’s cash balance to nearly $2 billion. For an early-stage aerospace firm, that’s not just padding. That’s survival capital.

With that kind of liquidity, Archer now has the flexibility to move through key milestones without going back to the market. FAA certification. Manufacturing scale-up. Infrastructure buildout. All of it costs money — and Archer just bought itself time.

That matters more than people might realize. eVTOL is not a market that rewards hesitation. It’s a race, and having the cash to move forward — confidently and at full speed — is a competitive edge.

More importantly, this wasn’t panic fundraising. The company wasn’t forced to raise at fire-sale levels. They chose to act while the stock was still elevated, sentiment was strong, and institutional demand was there. In doing so, they traded a short-term hit for long-term independence.

They also now have the financial firepower to deliver on their biggest public commitment yet: serving as the official air taxi provider for the 2028 Olympic Games in Los Angeles. That’s no small goal — and missing it would hurt credibility. Now, with the balance sheet fortified, the company can build with fewer detours or distractions.

What didn’t change?

• The tech didn’t break.

• The business model didn’t shift.

• The long-term strategy — and the regulatory backdrop — are both intact.

This was a reset in share price, not in thesis.

What the Smart Money Did

While retail investors were selling into the dip, one major buyer was doing the opposite: ARK Invest stepped in — hard.

On June 13, the same day Archer was trading near its lows, Cathie Wood’s ARK funds bought 3.43 million shares across three ETFs, including ARKK, ARKQ, and ARKX. That’s over $40 million in fresh capital — all added while most of the market was still processing the dilution.

This wasn’t a small top-up or passive rebalancing. It was a clear vote of confidence — and it came when sentiment was weakest.

Why does that matter?

Because ARK isn’t momentum-chasing here. They’ve held a position in ACHR for a while. They understand the tech, the commercialization roadmap, the regulatory hurdles. And they still chose to average down — during a sharp drop — rather than wait for a rebound.

That’s the kind of behavior you expect from investors with a multi-year view. They weren’t reacting to a headline. They were leaning into a fundamental story that just got stronger.

And their buying likely helped stabilize the stock. Volume surged that day, and by the next session, ACHR shares were already bouncing back. The rebound wasn’t driven by a press release or earnings revision — it was driven by buyers with conviction.

So if you’re wondering whether the drop signaled trouble, this was your answer: institutional money in the innovation space saw it as a discount worth taking.

Stronger Today Than Before the Drop

At first glance, it might seem odd to say a company is in better shape after its stock drops nearly 20%. But that’s exactly what happened here.

If we rewind to June 11 — the last close before the offering — here’s what Archer looked like:

• Trading above $12

• Supported by favorable policy news

• Riding a wave of bullish analyst sentiment

• But holding less than $1.2 billion in liquidity — and burning significant capital each quarter

Compare that to the post-raise position. As of mid-June, the fundamentals are meaningfully stronger across multiple dimensions:

1. A Fortress Balance Sheet

The $850 million raise brought Archer’s total cash to nearly $2 billion. That’s not just a cushion — it’s a full runway.

This new capital gives Archer the ability to:

• Ramp up U.S. manufacturing without delay

• Execute its “Midnight” production schedule

• Build out vertiport infrastructure where needed

• Sustain operating expenses into the back half of the decade

And crucially: it lowers capital risk. Prior to the raise, even bullish investors acknowledged that Archer would likely need to tap markets again before reaching commercialization. That concern is now off the table — or at the very least, pushed far enough out that it no longer affects short-term valuation.

If this were a pre-revenue biotech, this would be the equivalent of funding through FDA approval. In a capital-hungry industry like eVTOL aviation, securing funding before you need it is a strategic edge, not a cost.

2. Policy Tailwinds Just Kicked In

One of the biggest unknowns in the eVTOL space has always been regulatory timing. Will the FAA move fast enough? Will public infrastructure be ready? Will government agencies even take this seriously?

As of early June, those questions got a clearer answer.

The White House issued an executive order to formally launch an eVTOL integration pilot program, aimed at accelerating air taxi deployment in the U.S. While the market focused on the capital raise, this was arguably the more significant catalyst for the company’s long-term outlook.

Archer’s CEO called the order “a seminal moment” — and for good reason. It means:

• The FAA is now working on air taxi rulemaking with explicit federal backing

• Pilot cities and corridors could be established more quickly

• Public-private cooperation will likely expand

This doesn’t eliminate all risk. But it does mark a shift in tone — from “wait and see” to “let’s make this happen.”

And Archer is well-positioned to benefit, especially given its prior deals with United Airlines, its selection as the official air taxi for the 2028 Olympics, and its lead in certification readiness.

3. Global Commercial Traction Is Building

Just days after the capital raise, Archer announced its third international “Launch Edition” partnership — this time in Indonesia.

Under the deal, PT IKN Nusantara will purchase up to 50 Midnight aircraft, worth an estimated $250 million, to deploy air taxi service in Indonesia’s new smart city capital project. This follows earlier agreements in:

• The UAE, through a partnership with Abu Dhabi Aviation

• Ethiopia, with Ethiopian Airlines as the regional operator

These aren’t just paper MOUs. They’re early demand signals — tangible expressions of interest in deploying Midnight aircraft at scale.

For an investor trying to gauge whether this technology will find real-world demand, this is the answer. These agreements build Archer’s order book, give it international visibility, and potentially create network effects as early adopters generate proof-of-concept.

It’s also an important hedge: if FAA certification takes longer than expected, these international routes may go live sooner — creating commercial revenue ahead of U.S. deployment.

4. Analyst Support Remains Firm

You’d expect a big equity raise — especially one priced below market — to rattle the analyst community. But that’s not what happened.

Post-raise, most analysts either held their targets steady or made minor adjustments:

• Canaccord Genuity reaffirmed its “Buy” rating and lowered its target just slightly, from $13.50 to $13 — a modest change given the dilution

• HC Wainwright actually raised its target to $18 just days earlier, based on policy momentum and long-term upside

• As of mid-June, 7 out of 8 analysts covering ACHR rate it a Buy

And perhaps most telling: no major firm downgraded the stock after the raise.

That tells you one thing — Wall Street understands what Archer did and why. And more importantly, they’re not treating the dilution as a sign of weakness.

They see the raise for what it was: a strategic investment in execution capacity. Not a bailout. Not a delay. A setup for growth.

Bottom line: If you’re only watching the share price, it’s easy to think something broke. But zoom out, and Archer’s positioning — both financially and strategically — looks better than it did before the drop.

More cash.
More policy support.
More global partners.
Still backed by analysts.

That’s not deterioration. That’s progress — wrapped in a volatile chart.

Was the Drop Justified or Just Noise?

Let’s be clear — the drop in ACHR’s stock wasn’t irrational.

When a company issues 85 million new shares at $10, the math changes. Dilution means existing shareholders now own a smaller piece of the pie. If the market cap stays the same but the share count goes up, price per share adjusts downward. That’s not panic. That’s algebra.

The market saw the offering price — $10 — and brought the stock down to match it. That’s how price discovery works.

But here’s what matters: this was a one-time adjustment — not a shift in fundamentals. And that’s where the opportunity lies. The company is now:

• Fully funded through its next phase of growth

• Backed by favorable policy momentum

• Expanding internationally, even before FAA certification

• Endorsed — at scale — by ARK Invest and most major analysts

If you believed in the business on June 11 at $12.17, you should believe in it more at $10. And if you didn’t own it then, you’ve now been handed a better entry.

For us, this wasn’t a red flag. It was a gift — and we’re going to take it.

We don’t often get second chances to enter high-conviction names at better terms — especially after fundamentals have improved. But every once in a while, the market gives you one.

When that happens, you don’t ask twice.

You run with it.

That’s what I’m doing. I’m not just watching from the sidelines.

Today, I sold the ACHR October 2025 $9 put for $1.31 — a trade that gives me a wide buffer and a clear path to entry if the stock pulls back again.

I walk through the full setup and mechanics in the trade alert — but the thesis is simple: the stock is cheaper, the business is stronger, and I’m getting paid to take the other side of a temporary repricing.

Here’s the full setup:

Entry

Sold ACHR Oct 17 2025 $9 Put (123 DTE)
ACHR251017P00009000

Opened:        June 16, 2025
Entry Price:   $1.31
Exit Target:   $0.31 (To Close)

Underlying:    $10.38
Buffer:        13.28%
Breakeven:     $7.69

Max Risk:      $900.00
Return:        11.11%
Prob. of Win:  ~70%

Profit Target: $100.00

Thesis

ACHR just raised $850 million — not because it had to, but because it could. The company now has nearly $2 billion in cash, fresh commercial partnerships, and a clean path to the 2028 Olympics. But because of the dilution, the stock dropped — and volatility spiked.

That gave us a window.

By selling the $9 strike put, we’re:

• Giving ourselves a 13% cushion below the current price

• Locking in $100 of premium per contract if it decays to our exit target

• Taking the other side of a short-term repricing — and getting paid to do it

This is a name we want to own. This trade gives us a way to accumulate equity exposure without touching cash, and with a high likelihood of success.

What We Did With The Premium

We didn’t pocket the $100. We plowed it straight back into ACHR shares, buying at $10.27.

So even if the put never gets assigned, we’ve already added exposure — using premium, not principal.

This is what Collateral Compounding is all about:

Generate premium → reinvest it into names we believe in → repeat.

How It’s Managed

This is a set-and-forget trade.

• We’ve already placed a limit order to close at $0.31

• If the stock cooperates, the trade will close automatically, with no further action

• We’ve also set a delta alert at 0.60

  • If delta climbs that high, we’ll roll the trade back to a ~0.30 delta strike with fresh time

  • Otherwise, we leave it alone

We expect this to close well before expiration — and if it does, we’ll look to redeploy the capital again. Same name, or new target, we’ll decide then.

Status: Open

You already own stocks you believe in. You’re in it for the long haul.

But what if you could quietly add 5% a year to that portfolio — using no extra cash, just the margin capacity you already have?

Over 20 years, earning 10% turns $100,000 into $673,000. Add just 5% more, and that grows to $1.65 million.

Same portfolio. Same convictions. Just smarter compounding. That’s the idea behind Collateral Compounding: a strategy that builds new positions without taking anything away from the ones you already hold.

If you already have a portfolio of stocks you believe in, the last thing you need is another strategy that competes for capital.

Collateral Compounding doesn’t. It supplements what you already own by using margin — not cash — to build new positions at prices we like. We target undervalued stocks after deep corrections, high growth stories, cyclicals that are ready to rebound, and defensive dividend payers you can safely own for years. We sell puts tactically on these names and reinvest the premium into the underlying. No blind selling, no aimless assignments. Over time, we will help you build high conviction positions that could rival — or even outperform — your original holdings.

This isn’t about replacing your strategy. It’s about compounding smarter alongside it.

How This Strategy Works Without Using Any Cash

Collateral Compounding isn’t capital-intensive. You don’t need to sell anything. You don’t need to move cash. You don’t even need to change how you manage your core portfolio.

Instead, this strategy uses the buying power you already have — the margin unlocked by your existing long positions. And it stays entirely within those limits.

• No cash outlay.

• No interest charges.

• No disruption to your current holdings.

You’re not borrowing. You’re not leveraging. You’re simply putting idle buying power to work — collecting premium, reinvesting it into high-quality stocks at attractive valuations, and quietly compounding your long portfolio over time.

And because we only target stocks we’ve pre-screened for quality, valuation, and timing, you’re not just writing random puts. You’re methodically building equity exposure in names we think are worth owning for the next few years.

It’s a side engine — one that builds a second layer of wealth while your main portfolio keeps running, untouched.

A Real-World Example — Turning $0 Into $155 (in Days)

Let’s say you’re starting with a $10,000 portfolio.

We generally recommend allocating about 25% of your portfolio’s long value as your “assignment budget” when getting started — just enough to learn the rhythm of the strategy without overcommitting. On a $10,000 portfolio, that means your first few trades would target about $2,500 of potential assignment risk.

Here’s what that looked like in practice.

On May 19, 2025, we sold the ASTS June 27 $22 put for $1.59 — a total assignment risk of $2,200, comfortably within that 25% threshold.

Just 16 days later, we bought it back for $0.59, locking in our $100 profit target. The trade required no cash outlay — only the ability to take on that obligation — and it closed automatically once our target was hit.

What did we do with that $100?

We reinvested it into ASTS stock, buying 4.10 shares at $24.34. At the time of writing, those shares are trading around $38, turning our $100 premium into $155. That’s a 55% return on the premium alone, and more importantly:

That single trade quietly added 1.5% to the value of our original $10,000 portfolio — in just over two weeks.

And next time?

That 25% assignment budget isn’t based on $10,000 anymore. It’s based on $10,155 — which means we can now take on $2,538 of exposure, and so on.

That’s the idea behind Collateral Compounding: stacking small wins using unused margin capacity to build long-term positions. Repeated patiently, those wins start to add up. And over time, they compound.

Is This a Margin Strategy?

Technically, yes — but not the kind most people worry about.

We’re not borrowing money or paying interest. Instead, this strategy uses your available margin capacity — the reserve of buying power in your account — to secure put positions.

• No cash leaves your account.

• No loan is issued.

• No interest is charged.

Your broker simply sets aside a portion of your portfolio as collateral in case you get assigned. And because we structure trades to avoid assignment, your core capital stays untouched.

So while this strategy uses margin, it’s not leveraged in the traditional sense. It’s a controlled, efficient way to compound equity exposure without disrupting your portfolio.

What This Isn’t

This isn’t the Wheel. And it’s not a cash-secured put strategy.

Cash-secured puts tie up real cash, often sitting idle waiting for a stock to dip. The Wheel repeats a sell-assign-call cycle without much discretion — often selling puts on whatever yields the highest premium.

Collateral Compounding is different. It doesn’t lock up capital. It doesn’t sell indiscriminately. It targets high-conviction names using excess buying power instead of tying up funds.

We don’t chase yield. We don’t roll blindly. We’re building long-term positions — patiently, selectively — using buying power that most portfolios leave idle.

(Want a full breakdown of how the Wheel works — and how this diverges from it? We’ll cover that here soon.)

What You Need to Use This Strategy

To run Collateral Compounding, you’ll need a margin account with approval to sell uncovered puts — typically called Level 3 or Level 4, depending on your broker.

That’s because this strategy uses margin capacity (not cash) to secure put positions. You’re not borrowing, but you are using your portfolio as collateral — and that requires a higher level of options access.

Not sure if you qualify — or how to get approved? We’ve published a full guide that walks you through the process.

Who This Is (and Isn’t) For

Collateral Compounding is a strategy that runs alongside your core portfolio — not in place of it. We don’t dictate how you manage your existing holdings. You can trade them, rebalance them, or leave them alone. That’s your call.

But the positions we help you build — funded by your account’s existing buying power — require a different mindset.

This strategy only makes sense if you’re willing to:

• Hold these new positions for at least 2–3 years to allow our thesis to play out

• Stay disciplined during drawdowns, especially when volatility spikes

• Adjust position sizing if your core portfolio declines, since the buying power we employ is based on that value

These aren’t just trades. They’re equity positions we’re deliberately building — names we’ve screened, studied, and believe are worth owning for years. You didn’t spend cash to get them, but they still deserve your full commitment.

This strategy is not a good fit if:

• You expect every position to pay off in a few weeks or months

• You’re likely to close a trade just because it’s temporarily underwater

• You can’t tolerate volatility in names we’ve screened and selected

• You’re unwilling to hold these specific positions — built using margin — for multiple years

If you treat these like just another options income play — chasing premium, closing early, or bailing when things dip — it falls apart. There are plenty of ways to run a yield strategy. This isn’t one of them. What we’re doing is different: building long-term ownership in high-quality companies, one position at a time. And we need you to treat those positions with the respect that long-term ownership requires.

These are not short-term yield plays. They’re long-term equity entries — funded by premium, not capital — and they need time to develop.

If you treat them like trades, the strategy won’t work. But if you’re patient, the compounding will be meaningful.

(Curious how these positions take shape — and how we end up with long-term equity exposure without spending a dime of your capital? We’ll walk through the full mechanics in an upcoming article.)

How Much Time This Takes

This isn’t an active strategy. You’ll typically get just 1-2 setups per week — and each one takes minutes to enter.

Once you get the alert, you:

• Sell the put

• Set a closing order

• Set a rolling alert in your broker platform

After that, it manages itself. Most trades close automatically. If a roll is needed, your platform will let you know — no need to wait for me. Just roll it when the alert comes up. It’s quick and mechanical.

Going on vacation? Pause. I do too. This is a side strategy — not your main focus. I'd rather earn an extra 4% a year and miss a few setups than chase 8% and babysit trades all day.

The point is to compound quietly in the background — without getting in the way.

Where This Is Going

Collateral Compounding isn’t a one-off idea. It’s a full framework — and this is just the start.

In the coming weeks, I’ll walk through every part of the strategy in detail: How I select the names. How I manage the trades. When to roll. Why we pause. What to do when a position goes against you — and what success looks like when it doesn’t.

If you're interested in building long-term positions in quality companies without committing more capital, this strategy can help. It's not magic. It’s just structure, patience, and putting unused buying power to work.

More to come.

Regeneron Pharmaceuticals (regn) Comprehensive Investment Analysis

723KB ∙ PDF file

Download

Download

At its core, the report makes a bullish case: Regeneron is undervalued, underappreciated, and entering the next phase of its growth story. Its current valuation (≈13× forward earnings) doesn’t reflect the strength of its cash flows, the durability of its flagship immunology drug (Dupixent), or the size of the upside embedded in its late-stage pipeline. The authors believed REGN has 40% upside from here—with a bull case stretching as high as 70%.

But this isn’t just a momentum play or a "story stock." The bear case gets a full airing too. The company’s leading ophthalmology product (Eylea) is facing a slow-motion patent cliff. Competition is rising across its portfolio. And any stumbles in the pipeline—especially Dupixent's COPD data or its new oncology entrants—could capsize the growth narrative.

This piece walks through both sides of that thesis, with an eye to what’s already priced in, what still needs to go right, and how much risk remains if it doesn’t. I’ll explain where the upside could come from, how durable the existing business really is, and why the stock’s risk-reward profile may look better today than it did even a year ago.

As an uncovered option seller, I’m always looking at risk and downside first. That means studying the bear thesis before even thinking about upside. Many times when I’m selling volatility, I don’t care of the stock does well, especially in the short term. I just need to make sure it won’t fall of a cliff in the next 45-60 days. Let’s get into it and look at the report’s bear thesis:

Bear Thesis: What Was Supposed to Go Wrong — and What Actually Did

The bear case for Regeneron outlined five major risks. Some of them came true. Some didn’t. A few ended up flipping into outright positives. Here’s a breakdown of what was predicted, and where things actually stand.

1. Eylea Patent Cliff

Prediction: Regeneron’s flagship eye drug would face early biosimilar competition. The base case assumed a ~60% collapse in U.S. sales by 2026.

Reality: That cliff arrived early. Amgen launched its biosimilar in late 2024 after Regeneron lost a key injunction, and another biosimilar is set to follow in 2026. Sales have already taken a hit: standard-dose U.S. Eylea revenue fell 39% year-over-year in Q1 2025. High-dose Eylea is helping cushion the blow, but not enough to offset it entirely. The decline is happening fast — and mostly in line with the bear thesis. The key difference? This wasn’t a surprise. Investors saw it coming. Much of that downside now looks “priced in.”

2. Dupixent in COPD

Prediction: The expansion into chronic obstructive pulmonary disease (COPD) would flop — either on weak data or safety concerns — wiping out billions in future sales.

Reality: This one flipped completely. Dupixent became the first biologic ever approved for COPD in 2024. The data were strong, the label was clean, and the commercial potential is big. Analysts now expect ~$3.5 billion in new annual revenue from COPD alone. Instead of shrinking, Dupixent’s growth story got stronger. This removed a massive piece of the bear case.

3. New Competition in Atopic Dermatitis

Prediction: Lilly’s lebrikizumab would eat into Dupixent’s lead in eczema, pulling growth down to single digits by 2025.

Reality: Lebrikizumab is on the market (as Ebglyss), but it hasn’t moved the needle much. Dupixent still dominates and is growing at nearly 20% year-over-year. Ebglyss has a more convenient dosing schedule, and might slowly gain share, but it’s not disrupting the franchise. The bear case overestimated the competitive threat — at least so far.

4. Odronextamab Setback

Prediction: Odronextamab, Regeneron’s bispecific antibody for lymphoma, would get delayed or derailed — giving competitors like Roche and AbbVie a head start.

Reality: This one hit. The FDA rejected odronextamab’s initial application in 2024, citing the need for more data. Rivals are already on the market, and doctors are gaining comfort with those options. Regeneron is now playing catch-up. Approval is still possible (the drug is already approved in Europe), but the commercial window has narrowed. This leg of the bear thesis has largely played out.

5. Fianlimab Failure in Melanoma

Prediction: Regeneron’s LAG-3 antibody combo with Libtayo wouldn’t work — removing a key potential growth driver in melanoma.

Reality: Still TBD. Early data looked strong. But the Phase 3 readout has slipped into the back half of 2025, and the competitive field has moved forward. Even if the combo works, Regeneron will be a late entrant. So while there’s no evidence of failure, the best-case scenario is now a smaller piece of the pie. The risk is still live, but diminished.

Bull Thesis: What Was Supposed to Go Right And Where We Stand Now

When I first got handed this report, the bullish thesis for Regeneron was a classic multi-engine growth story. Dupixent would keep expanding into new indications. Eylea would decline, but gently. A deep pipeline would begin delivering. There was even a hope that a new class of assets — bispecifics, RNAi combos, LAG-3 immunotherapy — might each contribute hundreds of millions in new revenue.

Some of that has happened. Some hasn’t. Here’s a breakdown of what the bull case was at the time, and where things stand today, mid-2025.

Dupixent Expands into COPD — and It Works

Prediction: If Dupixent could replicate its success in asthma and eczema in COPD — a much larger, underserved market — it could easily add $3 billion in new revenue. That would extend its growth runway into the next decade, making it the most successful IL-4/IL-13 drug in history.

Reality: This is one of the cleanest wins for the bull case. In late 2024, the FDA approved Dupixent for COPD with type 2 inflammation — the first biologic ever approved for the condition. This wasn’t a token win either. The Phase 3 data was strong: a 30% reduction in exacerbations, good tolerability, and no black-box warnings.

Commercial uptake is early, but it’s happening. Pulmonologists have been slower to adopt biologics than dermatologists or allergists, but that’s changing. And unlike prior Dupixent launches, there’s almost no direct competition here. If sales follow the same curve as in asthma, this becomes a major new leg for the franchise.

Verdict: Core part of the bull thesis — and now confirmed. Execution is still key, but the thesis was right. This is the reason to consider a new position in Regeneron.

High-Dose Eylea Cushions the Patent Cliff — Or Not

Prediction: Regeneron would steer through the patent expiry on Eylea by pushing adoption of its new high-dose formulation. The base case assumed biosimilars wouldn’t launch until 2027 and that the company could retain much of its ~$5.9B U.S. Eylea business with less price pressure.

Reality: That didn’t play out. Amgen’s biosimilar launched in 2024 after Regeneron failed to block it in court. Another biosimilar is likely coming in 2026. Meanwhile, Q1 2025 data shows standard-dose U.S. Eylea revenue down 39% year-over-year. High-dose adoption has been slower than hoped — and not enough to offset the base erosion.

Investors knew this was coming, so some of the pain is already priced in. But it doesn’t change the fact that Eylea is now a shrinking asset, not a stabilizer.

Verdict: This leg of the bull case broke. Eylea is no longer a bridge to new growth — it’s a headwind.

Odronextamab and the Bispecifics Franchise

Prediction: Odronextamab — Regeneron’s CD20xCD3 bispecific antibody — would emerge as best-in-class for B-cell lymphomas. Approval in FL and DLBCL would unlock a $1B+ market, and Regeneron could leapfrog earlier entrants like Roche’s Lunsumio or AbbVie’s Epkinly.

Reality: The data was decent but not a breakout. Worse, the FDA issued a CRL (Complete Response Letter) in 2024 asking for longer follow-up. That put Regeneron behind competitors who are already on the market and gaining traction. Odronextamab might still get approved later this year — and Regeneron is the only player with data in both FL and DLBCL — but it’s clearly no longer a “category winner.”

Verdict: Still viable, but the market leadership angle is gone. At best, this becomes a supporting player, not a franchise.

Fianlimab + Libtayo: A Shot at the LAG-3 Class

Prediction: Regeneron’s LAG-3 antibody (fianlimab), when paired with its PD-1 drug Libtayo, could compete directly with BMS’s Opdualag in melanoma. If the combo hit its endpoints, it could establish Regeneron in the next wave of immuno-oncology.

Reality: The data so far is promising — strong overall response rates and progression-free survival. But the Phase 3 trial slipped into late 2025, pushing out the timeline. Meanwhile, Opdualag is entrenched and Merck is advancing its own LAG-3 combo. Even if Regeneron succeeds, it’ll be a second- or third-to-market entrant.

Still, the science is sound, and Regeneron has shown it can commercialize Libtayo effectively. A positive readout would give them a viable position in a meaningful oncology segment.

Verdict: A live option. Execution and timing will determine how valuable it becomes.

Pozelimab + Cemdisiran: A Rare Disease Wedge

Predition: By combining an RNAi agent with a monoclonal antibody, Regeneron could offer a novel treatment for PNH (a rare blood disease), potentially leapfrogging Alexion’s Soliris/Ultomiris franchise. If successful, it could validate Regeneron’s platform strategy and open doors to broader RNAi use.

Reality: The Phase 3 data was solid. No major safety concerns. The combo works — and may offer some dosing and tolerability advantages. Approval could come in 2026, and commercial runway exists (PNH is a ~$5B market globally). It’s a small niche, but an important one — especially because it’s Regeneron’s first real RNAi + antibody asset.

Verdict: Undervalued part of the bull case. The science is ahead of the stock price here.

“Smart” M&A with a $17B War Chest

Predition: Regeneron would deploy its massive cash position on smart acquisitions — not speculative moonshots, but near-term growth assets that could plug in fast.

Reality: The company has stayed active, but cautious. It bought Decibel Therapeutics for a gene therapy program, partnered with 23andMe for access to genetic data, and picked up a GLP-1/GIP dual agonist program. All early-stage bets. Nothing accretive in the short term. These may pay off down the road, but for now they’re R&D — not revenue.

Verdict: There is still some potential. But the market was hoping for something more tangible by now.

A Return to Growth — Eventually

Prediction: Even with Eylea in decline, Dupixent plus pipeline assets would return Regeneron to mid-teens top-line growth. With gross margins >80% and lean SG&A, earnings would scale quickly.

Reality: Not yet. Q1 2025 revenues were down year-over-year. Dupixent is growing ~20%, but that’s not enough to plug the Eylea gap — at least not yet. Management expects growth to reaccelerate in 2026 as Dupixent’s COPD launch scales and new approvals (like odronextamab) come online.

Verdict: Delayed, not derailed. But the window to deliver is getting narrower. It won’t happen this year.

Valuation Re-Rating — Still Waiting

Prediction: If growth resumed and the pipeline delivered, REGN’s P/E would re-rate to 18–20x — more in line with peers like Vertex or even Eli Lilly.

Reality: The market hasn’t moved. REGN still trades around 12x forward earnings, partly because of the Eylea overhang and pipeline delays. But if management can string together a few good quarters and COPD uptake accelerates, a re-rating is still plausible.

Verdict: The market wants proof — but the setup is there. It won’t happen this year.

My Take: Most of the Damage Is Done — But the Upside Isn’t

By mid-2025, the core of the bear thesis on Regeneron has already played out. The Eylea patent cliff came earlier than hoped and hit harder than bulls expected. Standard-dose revenue is falling fast, high-dose uptake has underwhelmed, and biosimilars are now a present-tense reality. On the pipeline side, odronextamab was delayed, not denied, and while the setback stung, it didn’t collapse the platform. The competitive threat to Dupixent in eczema turned out to be more noise than signal. The market has absorbed these blows — and Regeneron’s valuation reflects it.

That’s what makes the current setup interesting. The bad news isn’t hiding. It’s already all priced in.

At the same time, key elements of the bull case remain alive — and potentially transformative if they deliver over the next 6–18 months:

• COPD approval for Dupixent is a confirmed win. It’s the first biologic ever approved for this indication, and while uptake is early, the market size is large and the competitive landscape is wide open. This isn’t speculative anymore — it’s an execution story.

• Fianlimab (LAG-3) remains a real shot on goal. The Phase 3 readout is expected in late 2025. If it hits, Regeneron can credibly compete with BMS’s Opdualag in melanoma, opening a new immuno-oncology franchise around Libtayo.

• Pozelimab + Cemdisiran in PNH has real scientific edge. The Phase 3 data was clean. The combo showcases Regeneron’s RNAi + antibody approach, and if approved in 2026, could generate meaningful revenue in a rare disease space with limited competition.

• Growth reacceleration could begin in 2026. With Eylea declines front-loaded and Dupixent expanding into COPD, the company may return to mid-teens revenue growth next year. Margins remain excellent, and the operating structure is built for scalability.

• Valuation remains undemanding. REGN is still trading around 12× forward earnings — far below peers with similar pipelines and better-than-average balance sheets. Even modest execution could support a rerating toward 15×–18×, especially if Dupixent sales begin to outpace Eylea erosion.

That brings us to positioning.

My Trade: Short REGN Puts

At this price level — with sentiment beaten down, the major bearish risks already surfaced, and bullish drivers still live — the risk/reward skews positively for put sellers. The business remains highly profitable and cash-rich. It’s not a turnaround bet. It’s a temporary growth pause in a high-margin innovator.

If you're comfortable owning the stock at lower levels, selling puts at or slightly below current support offers a way to get paid while waiting for the pipeline to resolve. Even if the bullish outcomes take longer than expected — or don’t fully materialize — much of the downside already appears priced in. And if COPD uptake accelerates or the PNH or LAG-3 programs surprise to the upside, you’re positioned to benefit.

Put simply: the bear case is largely behind us. The bull case is still ahead. And the market is paying you to wait.

This isn’t a momentum trade. It’s a valuation + pipeline setup with a defined floor. If you're looking for asymmetric return profiles in biotech, this one deserves a place on the list.

Sold REGN Aug 15 2025 $475 Put (63 DTE)  
REGN250815P00475000

Opened:        June 13, 2025  
Entry Price:   $15.40  
Exit Target:   $5.40 (To Close)

Underlying:    $529.24  
Buffer:        13.1%  
Breakeven:     $459.60

Max Risk:      $47,500  
Return:        2.1%  
Prob. of Win:  ~75%

Profit Target: $1,000

On June 13, I sold the August $475 put on Regeneron for $15.40, collecting $1,540 in premium for each contract sold. At the time, the stock was trading around $530. My break-even on the trade is $459.60. I doubt $475 will even be re-tested. I think this position is going to be closing early unless there is more macro noise.

This is a straightforward premium capture setup. I’m targeting a buyback at $5.40, which would lock in a $1,000 profit on each contract I sold. The trade had 64 days to expiration at entry, but I expect to close it much earlier if the stock holds steady and the option decays on schedule.

There’s no plan to hold through expiration or roll. If REGN sells off sharply due to macro issues, I’ll be really happy to own a lot of it at $475. I also immediately deployed the $1000 per contract into a long position in REGN at $530. I think 2-3 years from now I’ll be exiting this position with REGN at $800-900. In the meantime, I’m happy to be paid to wait as Regeneron’s pipeline plays itself out.

Status: Open

This constant downward fall in interest rates over the past decades is what has allowed bond funds to perform well over the years. But that is going to be impossible going forward, because the interest rate cannot fall any further. And beginning in mid-August, the treasury yield bottomed out and is now rising again. If you have any mutual fund which purchases long-term bonds (20/30 years) of any kind (treasuries, emerging markets, corporate bonds), that's the worst case scenario. Those funds will lose around 15-20% of their value for every 1% increase in interest rates. A 2-3% increase in the interest rate will cut their value in half. Rates have already gone from 0.60% to 0.87% just in the month of October. That's a 27% increase in the interest rate in just 1 month. I've attached a chart where you can see that the interest rate has begun its move upward after bottoming out after the pandemic hit in Feb/Mar.

I've also attached a graphic of M2, (the money supply), over my lifetime. When you see the amount of money that the Federal Reserve has printed due to COVID19 and the deficit that the country is running, I believe it will be impossible to think that inflation will stay as low in the future as it has been in the past. And if inflation begins to rise, interest rates will have to rise to combat that if the Federal Reserve plans on controlling inflation.

That's why I feel there's no reason to own any bond fund at this time, not until interest rates have risen again back to a somewhat normal level. I think a lot of baby boomers are going to see a large portion of their retirement wiped out by an armageddon of falling bond prices. Please speak to whoever helps you plan your finances/retirement and take a hard look if it makes sense for you to own any bonds in the current interest rate environment.

Stay safe!